id	sid	tid	token	lemma	pos
dti-2355	1	1	dti	dti	PROPN
dti-2355	1	2	drug	drug	PROPN
dti-2355	1	3	target	target	NOUN
dti-2355	1	4	insights	insight	NOUN
dti-2355	1	5	2022	2022	NUM
dti-2355	1	6	;	;	PUNCT
dti-2355	1	7	16	16	NUM
dti-2355	1	8	:	:	SYM
dti-2355	1	9	1	1	NUM
dti-2355	1	10	-	-	SYM
dti-2355	1	11	5	5	NUM
dti-2355	1	12	issn	issn	PROPN
dti-2355	1	13	1177	1177	NUM
dti-2355	1	14	-	-	SYM
dti-2355	1	15	3928	3928	NUM
dti-2355	1	16	|	|	ADV
dti-2355	1	17	doi	doi	NOUN
dti-2355	1	18	:	:	PUNCT
dti-2355	1	19	10.33393	10.33393	NUM
dti-2355	1	20	/	/	SYM
dti-2355	1	21	dti.2022.2355	dti.2022.2355	PROPN
dti-2355	1	22	case	case	NOUN
dti-2355	1	23	report	report	NOUN
dti-2355	1	24	drug	drug	NOUN
dti-2355	1	25	target	target	NOUN
dti-2355	1	26	insights	insight	NOUN
dti-2355	1	27	issn	issn	VERB
dti-2355	1	28	1177	1177	NUM
dti-2355	1	29	-	-	SYM
dti-2355	1	30	3928	3928	NUM
dti-2355	1	31	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2355	1	32	©	©	PROPN
dti-2355	1	33	2022	2022	NUM
dti-2355	1	34	the	the	DET
dti-2355	1	35	authors	author	NOUN
dti-2355	1	36	.	.	PUNCT
dti-2355	2	1	this	this	DET
dti-2355	2	2	article	article	NOUN
dti-2355	2	3	is	be	AUX
dti-2355	2	4	published	publish	VERB
dti-2355	2	5	by	by	ADP
dti-2355	2	6	aboutscience	aboutscience	NOUN
dti-2355	2	7	and	and	CCONJ
dti-2355	2	8	licensed	license	VERB
dti-2355	2	9	under	under	ADP
dti-2355	2	10	creative	creative	ADJ
dti-2355	2	11	commons	common	NOUN
dti-2355	2	12	attribution	attribution	NOUN
dti-2355	2	13	-	-	PUNCT
dti-2355	2	14	noncommercial	noncommercial	ADJ
dti-2355	2	15	4.0	4.0	NUM
dti-2355	2	16	international	international	NOUN
dti-2355	2	17	(	(	PUNCT
dti-2355	2	18	cc	cc	NOUN
dti-2355	2	19	by	by	ADP
dti-2355	2	20	-	-	PUNCT
dti-2355	2	21	nc	nc	PROPN
dti-2355	2	22	4.0	4.0	NUM
dti-2355	2	23	)	)	PUNCT
dti-2355	2	24	.	.	PUNCT
dti-2355	3	1	commercial	commercial	ADJ
dti-2355	3	2	use	use	NOUN
dti-2355	3	3	is	be	AUX
dti-2355	3	4	not	not	PART
dti-2355	3	5	permitted	permit	VERB
dti-2355	3	6	and	and	CCONJ
dti-2355	3	7	is	be	AUX
dti-2355	3	8	subject	subject	ADJ
dti-2355	3	9	to	to	ADP
dti-2355	3	10	publisher	publisher	NOUN
dti-2355	3	11	’s	’s	PART
dti-2355	3	12	permissions	permission	NOUN
dti-2355	3	13	.	.	PUNCT
dti-2355	4	1	full	full	ADJ
dti-2355	4	2	information	information	NOUN
dti-2355	4	3	is	be	AUX
dti-2355	4	4	available	available	ADJ
dti-2355	4	5	at	at	ADP
dti-2355	4	6	www.aboutscience.eu	www.aboutscience.eu	PROPN
dti-2355	4	7	erythrodermic	erythrodermic	ADJ
dti-2355	4	8	psoriasis	psoriasis	NOUN
dti-2355	4	9	and	and	CCONJ
dti-2355	4	10	palmoplantar	palmoplantar	NOUN
dti-2355	4	11	hyperkeratosis	hyperkeratosis	AUX
dti-2355	4	12	successfully	successfully	ADV
dti-2355	4	13	treated	treat	VERB
dti-2355	4	14	with	with	ADP
dti-2355	4	15	secukinumab	secukinumab	NOUN
dti-2355	4	16	:	:	PUNCT
dti-2355	4	17	a	a	DET
dti-2355	4	18	case	case	NOUN
dti-2355	4	19	report	report	NOUN
dti-2355	4	20	martino	martino	PROPN
dti-2355	4	21	carriero	carriero	PROPN
dti-2355	4	22	dermatology	dermatology	PROPN
dti-2355	4	23	unit	unit	NOUN
dti-2355	4	24	,	,	PUNCT
dti-2355	4	25	poliambulatorio	poliambulatorio	NOUN
dti-2355	4	26	grottaglie	grottaglie	PROPN
dti-2355	4	27	,	,	PUNCT
dti-2355	4	28	grottaglie	grottaglie	PROPN
dti-2355	4	29	italy	italy	PROPN
dti-2355	4	30	abstract	abstract	ADJ
dti-2355	4	31	introduction	introduction	NOUN
dti-2355	4	32	:	:	PUNCT
dti-2355	4	33	erythrodermic	erythrodermic	ADJ
dti-2355	4	34	psoriasis	psoriasis	NOUN
dti-2355	4	35	(	(	PUNCT
dti-2355	4	36	ep	ep	PROPN
dti-2355	4	37	)	)	PUNCT
dti-2355	4	38	is	be	AUX
dti-2355	4	39	a	a	DET
dti-2355	4	40	rare	rare	ADJ
dti-2355	4	41	and	and	CCONJ
dti-2355	4	42	severe	severe	ADJ
dti-2355	4	43	form	form	NOUN
dti-2355	4	44	of	of	ADP
dti-2355	4	45	psoriasis	psoriasis	NOUN
dti-2355	4	46	that	that	PRON
dti-2355	4	47	affects	affect	VERB
dti-2355	4	48	1	1	NUM
dti-2355	4	49	%	%	NOUN
dti-2355	4	50	to	to	PART
dti-2355	4	51	2.25	2.25	NUM
dti-2355	4	52	%	%	NOUN
dti-2355	4	53	of	of	ADP
dti-2355	4	54	patients	patient	NOUN
dti-2355	4	55	,	,	PUNCT
dti-2355	4	56	increasing	increase	VERB
dti-2355	4	57	mortality	mortality	NOUN
dti-2355	4	58	risk	risk	NOUN
dti-2355	4	59	.	.	PUNCT
dti-2355	5	1	to	to	ADP
dti-2355	5	2	date	date	NOUN
dti-2355	5	3	,	,	PUNCT
dti-2355	5	4	very	very	ADV
dti-2355	5	5	few	few	ADJ
dti-2355	5	6	therapies	therapy	NOUN
dti-2355	5	7	have	have	AUX
dti-2355	5	8	been	be	AUX
dti-2355	5	9	approved	approve	VERB
dti-2355	5	10	for	for	ADP
dti-2355	5	11	the	the	DET
dti-2355	5	12	treatment	treatment	NOUN
dti-2355	5	13	of	of	ADP
dti-2355	5	14	this	this	DET
dti-2355	5	15	condition	condition	NOUN
dti-2355	5	16	.	.	PUNCT
dti-2355	6	1	recently	recently	ADV
dti-2355	6	2	,	,	PUNCT
dti-2355	6	3	biological	biological	ADJ
dti-2355	6	4	therapies	therapy	NOUN
dti-2355	6	5	that	that	PRON
dti-2355	6	6	specifically	specifically	ADV
dti-2355	6	7	target	target	VERB
dti-2355	6	8	inflammatory	inflammatory	ADJ
dti-2355	6	9	cytokines	cytokine	NOUN
dti-2355	6	10	have	have	AUX
dti-2355	6	11	improved	improve	VERB
dti-2355	6	12	the	the	DET
dti-2355	6	13	management	management	NOUN
dti-2355	6	14	and	and	CCONJ
dti-2355	6	15	treatment	treatment	NOUN
dti-2355	6	16	of	of	ADP
dti-2355	6	17	ep	ep	PROPN
dti-2355	6	18	.	.	PROPN
dti-2355	6	19	secukinumab	secukinumab	PROPN
dti-2355	6	20	,	,	PUNCT
dti-2355	6	21	a	a	DET
dti-2355	6	22	human	human	ADJ
dti-2355	6	23	monoclonal	monoclonal	NOUN
dti-2355	6	24	antibody	antibody	NOUN
dti-2355	6	25	that	that	PRON
dti-2355	6	26	specifically	specifically	ADV
dti-2355	6	27	targets	target	VERB
dti-2355	6	28	interleukin-17a	interleukin-17a	PROPN
dti-2355	6	29	(	(	PUNCT
dti-2355	6	30	il-17a	il-17a	PROPN
dti-2355	6	31	)	)	PUNCT
dti-2355	6	32	,	,	PUNCT
dti-2355	6	33	has	have	AUX
dti-2355	6	34	been	be	AUX
dti-2355	6	35	shown	show	VERB
dti-2355	6	36	to	to	PART
dti-2355	6	37	be	be	AUX
dti-2355	6	38	beneficial	beneficial	ADJ
dti-2355	6	39	in	in	ADP
dti-2355	6	40	different	different	ADJ
dti-2355	6	41	psoriasis	psoriasis	NOUN
dti-2355	6	42	settings	setting	NOUN
dti-2355	6	43	.	.	PUNCT
dti-2355	7	1	methods	method	NOUN
dti-2355	7	2	:	:	PUNCT
dti-2355	7	3	we	we	PRON
dti-2355	7	4	report	report	VERB
dti-2355	7	5	the	the	DET
dti-2355	7	6	case	case	NOUN
dti-2355	7	7	of	of	ADP
dti-2355	7	8	a	a	DET
dti-2355	7	9	72	72	NUM
dti-2355	7	10	-	-	PUNCT
dti-2355	7	11	year	year	NOUN
dti-2355	7	12	-	-	PUNCT
dti-2355	7	13	old	old	ADJ
dti-2355	7	14	man	man	NOUN
dti-2355	7	15	affected	affect	VERB
dti-2355	7	16	by	by	ADP
dti-2355	7	17	persistent	persistent	ADJ
dti-2355	7	18	ep	ep	PROPN
dti-2355	7	19	and	and	CCONJ
dti-2355	7	20	severe	severe	ADJ
dti-2355	7	21	palmoplantar	palmoplantar	NOUN
dti-2355	7	22	hyperkeratosis	hyperkeratosis	VERB
dti-2355	7	23	whose	whose	DET
dti-2355	7	24	condition	condition	NOUN
dti-2355	7	25	was	be	AUX
dti-2355	7	26	not	not	PART
dti-2355	7	27	resolved	resolve	VERB
dti-2355	7	28	after	after	ADP
dti-2355	7	29	two	two	NUM
dti-2355	7	30	rounds	round	NOUN
dti-2355	7	31	of	of	ADP
dti-2355	7	32	treatment	treatment	NOUN
dti-2355	7	33	with	with	ADP
dti-2355	7	34	prednisone	prednisone	NOUN
dti-2355	7	35	and	and	CCONJ
dti-2355	7	36	therapy	therapy	NOUN
dti-2355	7	37	with	with	ADP
dti-2355	7	38	cyclosporine	cyclosporine	NOUN
dti-2355	7	39	.	.	PUNCT
dti-2355	8	1	results	result	NOUN
dti-2355	8	2	and	and	CCONJ
dti-2355	8	3	conclusions	conclusion	NOUN
dti-2355	8	4	:	:	PUNCT
dti-2355	8	5	treatment	treatment	NOUN
dti-2355	8	6	with	with	ADP
dti-2355	8	7	secukinumab	secukinumab	NOUN
dti-2355	8	8	significantly	significantly	ADV
dti-2355	8	9	improved	improve	VERB
dti-2355	8	10	the	the	DET
dti-2355	8	11	symptoms	symptom	NOUN
dti-2355	8	12	of	of	ADP
dti-2355	8	13	palmoplantar	palmoplantar	NOUN
dti-2355	8	14	hyperkeratosis	hyperkeratosis	PROPN
dti-2355	8	15	as	as	ADV
dti-2355	8	16	early	early	ADV
dti-2355	8	17	as	as	ADP
dti-2355	8	18	the	the	DET
dti-2355	8	19	first	first	ADJ
dti-2355	8	20	week	week	NOUN
dti-2355	8	21	,	,	PUNCT
dti-2355	8	22	with	with	ADP
dti-2355	8	23	a	a	DET
dti-2355	8	24	decrease	decrease	NOUN
dti-2355	8	25	of	of	ADP
dti-2355	8	26	psoriasis	psoriasis	NOUN
dti-2355	8	27	area	area	NOUN
dti-2355	8	28	and	and	CCONJ
dti-2355	8	29	severity	severity	NOUN
dti-2355	8	30	index	index	NOUN
dti-2355	8	31	(	(	PUNCT
dti-2355	8	32	pasi	pasi	NOUN
dti-2355	8	33	)	)	PUNCT
dti-2355	8	34	score	score	NOUN
dti-2355	8	35	from	from	ADP
dti-2355	8	36	60	60	NUM
dti-2355	8	37	to	to	PART
dti-2355	8	38	10	10	NUM
dti-2355	8	39	,	,	PUNCT
dti-2355	8	40	showing	show	VERB
dti-2355	8	41	almost	almost	ADV
dti-2355	8	42	complete	complete	ADJ
dti-2355	8	43	remission	remission	NOUN
dti-2355	8	44	after	after	ADP
dti-2355	8	45	1	1	NUM
dti-2355	8	46	month	month	NOUN
dti-2355	8	47	.	.	PUNCT
dti-2355	9	1	consistent	consistent	ADJ
dti-2355	9	2	with	with	ADP
dti-2355	9	3	the	the	DET
dti-2355	9	4	current	current	ADJ
dti-2355	9	5	literature	literature	NOUN
dti-2355	9	6	,	,	PUNCT
dti-2355	9	7	secukinumab	secukinumab	NOUN
dti-2355	9	8	treatment	treatment	NOUN
dti-2355	9	9	showed	show	VERB
dti-2355	9	10	promising	promise	VERB
dti-2355	9	11	and	and	CCONJ
dti-2355	9	12	encouraging	encourage	VERB
dti-2355	9	13	clinical	clinical	ADJ
dti-2355	9	14	outcomes	outcome	NOUN
dti-2355	9	15	in	in	ADP
dti-2355	9	16	the	the	DET
dti-2355	9	17	treatment	treatment	NOUN
dti-2355	9	18	of	of	ADP
dti-2355	9	19	the	the	DET
dti-2355	9	20	patient	patient	NOUN
dti-2355	9	21	’s	’s	PART
dti-2355	9	22	ep	ep	PROPN
dti-2355	9	23	.	.	PUNCT
dti-2355	10	1	however	however	ADV
dti-2355	10	2	,	,	PUNCT
dti-2355	10	3	more	more	ADJ
dti-2355	10	4	studies	study	NOUN
dti-2355	10	5	are	be	AUX
dti-2355	10	6	needed	need	VERB
dti-2355	10	7	to	to	PART
dti-2355	10	8	clarify	clarify	VERB
dti-2355	10	9	the	the	DET
dti-2355	10	10	il-17	il-17	ADV
dti-2355	10	11	-	-	PUNCT
dti-2355	10	12	dependent	dependent	ADJ
dti-2355	10	13	mechanism	mechanism	NOUN
dti-2355	10	14	in	in	ADP
dti-2355	10	15	the	the	DET
dti-2355	10	16	pathophysiology	pathophysiology	NOUN
dti-2355	10	17	of	of	ADP
dti-2355	10	18	ep	ep	PROPN
dti-2355	10	19	.	.	PUNCT
dti-2355	11	1	keywords	keyword	NOUN
dti-2355	11	2	:	:	PUNCT
dti-2355	11	3	biologic	biologic	NOUN
dti-2355	11	4	therapy	therapy	NOUN
dti-2355	11	5	,	,	PUNCT
dti-2355	11	6	erythrodermic	erythrodermic	ADJ
dti-2355	11	7	psoriasis	psoriasis	NOUN
dti-2355	11	8	,	,	PUNCT
dti-2355	11	9	interleukin-17	interleukin-17	NOUN
dti-2355	11	10	,	,	PUNCT
dti-2355	11	11	monoclonal	monoclonal	NOUN
dti-2355	11	12	antibody	antibody	NOUN
dti-2355	11	13	,	,	PUNCT
dti-2355	11	14	palmoplantar	palmoplantar	NOUN
dti-2355	11	15	hyperkeratosis	hyperkeratosis	NOUN
dti-2355	11	16	,	,	PUNCT
dti-2355	11	17	secukinumab	secukinumab	NOUN
dti-2355	11	18	received	receive	VERB
dti-2355	11	19	:	:	PUNCT
dti-2355	11	20	november	november	PROPN
dti-2355	11	21	4	4	NUM
dti-2355	11	22	,	,	PUNCT
dti-2355	11	23	2021	2021	NUM
dti-2355	11	24	accepted	accept	VERB
dti-2355	11	25	:	:	PUNCT
dti-2355	11	26	february	february	PROPN
dti-2355	11	27	23	23	NUM
dti-2355	11	28	,	,	PUNCT
dti-2355	11	29	2022	2022	NUM
dti-2355	11	30	published	publish	VERB
dti-2355	11	31	online	online	ADV
dti-2355	11	32	:	:	PUNCT
dti-2355	11	33	march	march	PROPN
dti-2355	11	34	7	7	NUM
dti-2355	11	35	,	,	PUNCT
dti-2355	11	36	2022	2022	NUM
dti-2355	11	37	corresponding	correspond	VERB
dti-2355	11	38	author	author	NOUN
dti-2355	11	39	:	:	PUNCT
dti-2355	11	40	martino	martino	PROPN
dti-2355	11	41	carriero	carriero	PROPN
dti-2355	11	42	dermatology	dermatology	PROPN
dti-2355	11	43	unit	unit	NOUN
dti-2355	11	44	poliambulatorio	poliambulatorio	PROPN
dti-2355	11	45	grottaglie	grottaglie	PROPN
dti-2355	11	46	via	via	ADP
dti-2355	11	47	tiziano	tiziano	PROPN
dti-2355	11	48	26	26	NUM
dti-2355	11	49	grottaglie	grottaglie	NOUN
dti-2355	11	50	(	(	PUNCT
dti-2355	11	51	ta	ta	NOUN
dti-2355	11	52	)	)	PUNCT
dti-2355	11	53	,	,	PUNCT
dti-2355	11	54	74023	74023	NUM
dti-2355	11	55	italy	italy	PROPN
dti-2355	11	56	dott.martino.carriero@alice.it	dott.martino.carriero@alice.it	PROPN
dti-2355	11	57	joints	joint	NOUN
dti-2355	11	58	,	,	PUNCT
dti-2355	11	59	nails	nail	NOUN
dti-2355	11	60	,	,	PUNCT
dti-2355	11	61	and	and	CCONJ
dti-2355	11	62	other	other	ADJ
dti-2355	11	63	organs	organ	NOUN
dti-2355	11	64	(	(	PUNCT
dti-2355	11	65	2	2	NUM
dti-2355	11	66	)	)	PUNCT
dti-2355	11	67	.	.	PUNCT
dti-2355	12	1	currently	currently	ADV
dti-2355	12	2	,	,	PUNCT
dti-2355	12	3	there	there	PRON
dti-2355	12	4	is	be	VERB
dti-2355	12	5	no	no	DET
dti-2355	12	6	cure	cure	NOUN
dti-2355	12	7	available	available	ADJ
dti-2355	12	8	,	,	PUNCT
dti-2355	12	9	and	and	CCONJ
dti-2355	12	10	psoriasis	psoriasis	NOUN
dti-2355	12	11	imposes	impose	VERB
dti-2355	12	12	a	a	DET
dti-2355	12	13	substantial	substantial	ADJ
dti-2355	12	14	negative	negative	ADJ
dti-2355	12	15	impact	impact	NOUN
dti-2355	12	16	on	on	ADP
dti-2355	12	17	the	the	DET
dti-2355	12	18	quality	quality	NOUN
dti-2355	12	19	of	of	ADP
dti-2355	12	20	life	life	NOUN
dti-2355	12	21	(	(	PUNCT
dti-2355	12	22	qol	qol	NOUN
dti-2355	12	23	)	)	PUNCT
dti-2355	12	24	of	of	ADP
dti-2355	12	25	patients	patient	NOUN
dti-2355	12	26	.	.	PUNCT
dti-2355	13	1	psoriasis	psoriasis	NOUN
dti-2355	13	2	can	can	AUX
dti-2355	13	3	occur	occur	VERB
dti-2355	13	4	at	at	ADP
dti-2355	13	5	any	any	DET
dti-2355	13	6	age	age	NOUN
dti-2355	13	7	and	and	CCONJ
dti-2355	13	8	is	be	AUX
dti-2355	13	9	most	most	ADV
dti-2355	13	10	common	common	ADJ
dti-2355	13	11	in	in	ADP
dti-2355	13	12	the	the	DET
dti-2355	13	13	age	age	NOUN
dti-2355	13	14	group	group	NOUN
dti-2355	13	15	50	50	NUM
dti-2355	13	16	-	-	SYM
dti-2355	13	17	69	69	NUM
dti-2355	13	18	years	year	NOUN
dti-2355	13	19	.	.	PUNCT
dti-2355	14	1	the	the	DET
dti-2355	14	2	reported	report	VERB
dti-2355	14	3	country	country	NOUN
dti-2355	14	4	-	-	PUNCT
dti-2355	14	5	specific	specific	ADJ
dti-2355	14	6	prevalence	prevalence	NOUN
dti-2355	14	7	of	of	ADP
dti-2355	14	8	psoriasis	psoriasis	NOUN
dti-2355	14	9	ranges	range	VERB
dti-2355	14	10	between	between	ADP
dti-2355	14	11	0.09	0.09	NUM
dti-2355	14	12	%	%	NOUN
dti-2355	14	13	and	and	CCONJ
dti-2355	14	14	11.4	11.4	NUM
dti-2355	14	15	%	%	NOUN
dti-2355	14	16	,	,	PUNCT
dti-2355	14	17	making	make	VERB
dti-2355	14	18	psoriasis	psoriasis	NOUN
dti-2355	14	19	a	a	DET
dti-2355	14	20	serious	serious	ADJ
dti-2355	14	21	global	global	ADJ
dti-2355	14	22	problem	problem	NOUN
dti-2355	14	23	(	(	PUNCT
dti-2355	14	24	1	1	NUM
dti-2355	14	25	)	)	PUNCT
dti-2355	14	26	,	,	PUNCT
dti-2355	14	27	with	with	ADP
dti-2355	14	28	approximately	approximately	ADV
dti-2355	14	29	3	3	NUM
dti-2355	14	30	%	%	NOUN
dti-2355	14	31	of	of	ADP
dti-2355	14	32	the	the	DET
dti-2355	14	33	us	us	PROPN
dti-2355	14	34	population	population	NOUN
dti-2355	14	35	and	and	CCONJ
dti-2355	14	36	around	around	ADV
dti-2355	14	37	125	125	NUM
dti-2355	14	38	million	million	NUM
dti-2355	14	39	people	people	NOUN
dti-2355	14	40	affected	affect	VERB
dti-2355	14	41	worldwide	worldwide	ADV
dti-2355	14	42	,	,	PUNCT
dti-2355	14	43	ranging	range	VERB
dti-2355	14	44	from	from	ADP
dti-2355	14	45	0.5	0.5	NUM
dti-2355	14	46	%	%	NOUN
dti-2355	14	47	in	in	ADP
dti-2355	14	48	asian	asian	ADJ
dti-2355	14	49	regions	region	NOUN
dti-2355	14	50	to	to	ADP
dti-2355	14	51	8	8	NUM
dti-2355	14	52	%	%	NOUN
dti-2355	14	53	of	of	ADP
dti-2355	14	54	the	the	DET
dti-2355	14	55	population	population	NOUN
dti-2355	14	56	in	in	ADP
dti-2355	14	57	norway	norway	PROPN
dti-2355	14	58	.	.	PUNCT
dti-2355	15	1	male	male	ADJ
dti-2355	15	2	and	and	CCONJ
dti-2355	15	3	female	female	ADJ
dti-2355	15	4	populations	population	NOUN
dti-2355	15	5	are	be	AUX
dti-2355	15	6	equally	equally	ADV
dti-2355	15	7	affected	affect	VERB
dti-2355	15	8	in	in	ADP
dti-2355	15	9	most	most	ADJ
dti-2355	15	10	regions	region	NOUN
dti-2355	15	11	(	(	PUNCT
dti-2355	15	12	3	3	NUM
dti-2355	15	13	)	)	PUNCT
dti-2355	15	14	.	.	PUNCT
dti-2355	16	1	psoriasis	psoriasis	NOUN
dti-2355	16	2	may	may	AUX
dti-2355	16	3	occur	occur	VERB
dti-2355	16	4	in	in	ADP
dti-2355	16	5	different	different	ADJ
dti-2355	16	6	forms	form	NOUN
dti-2355	16	7	,	,	PUNCT
dti-2355	16	8	such	such	ADJ
dti-2355	16	9	as	as	ADP
dti-2355	16	10	plaque	plaque	NOUN
dti-2355	16	11	psoriasis	psoriasis	NOUN
dti-2355	16	12	(	(	PUNCT
dti-2355	16	13	characterized	characterize	VERB
dti-2355	16	14	by	by	ADP
dti-2355	16	15	dry	dry	ADJ
dti-2355	16	16	scaly	scaly	NOUN
dti-2355	16	17	patches	patch	NOUN
dti-2355	16	18	)	)	PUNCT
dti-2355	16	19	,	,	PUNCT
dti-2355	16	20	which	which	PRON
dti-2355	16	21	represents	represent	VERB
dti-2355	16	22	80%-90	80%-90	NUM
dti-2355	16	23	%	%	NOUN
dti-2355	16	24	of	of	ADP
dti-2355	16	25	psoriasis	psoriasis	NOUN
dti-2355	16	26	cases	case	NOUN
dti-2355	16	27	;	;	PUNCT
dti-2355	16	28	pustular	pustular	ADJ
dti-2355	16	29	psoriasis	psoriasis	NOUN
dti-2355	16	30	(	(	PUNCT
dti-2355	16	31	contains	contain	VERB
dti-2355	16	32	puslike	puslike	ADJ
dti-2355	16	33	fluid	fluid	NOUN
dti-2355	16	34	mainly	mainly	ADV
dti-2355	16	35	infiltrated	infiltrate	VERB
dti-2355	16	36	with	with	ADP
dti-2355	16	37	white	white	ADJ
dti-2355	16	38	blood	blood	NOUN
dti-2355	16	39	cells	cell	NOUN
dti-2355	16	40	)	)	PUNCT
dti-2355	16	41	;	;	PUNCT
dti-2355	16	42	erythrodermic	erythrodermic	ADJ
dti-2355	16	43	psoriasis	psoriasis	NOUN
dti-2355	16	44	(	(	PUNCT
dti-2355	16	45	ep	ep	NOUN
dti-2355	16	46	,	,	PUNCT
dti-2355	16	47	characterized	characterize	VERB
dti-2355	16	48	by	by	ADP
dti-2355	16	49	exfoliation	exfoliation	NOUN
dti-2355	16	50	of	of	ADP
dti-2355	16	51	fine	fine	ADJ
dti-2355	16	52	scaly	scaly	NOUN
dti-2355	16	53	skin	skin	NOUN
dti-2355	16	54	with	with	ADP
dti-2355	16	55	pain	pain	NOUN
dti-2355	16	56	and	and	CCONJ
dti-2355	16	57	itching	itching	NOUN
dti-2355	16	58	)	)	PUNCT
dti-2355	16	59	;	;	PUNCT
dti-2355	16	60	guttate	guttate	VERB
dti-2355	16	61	psoriasis	psoriasis	NOUN
dti-2355	16	62	(	(	PUNCT
dti-2355	16	63	characterized	characterize	VERB
dti-2355	16	64	by	by	ADP
dti-2355	16	65	drop	drop	NOUN
dti-2355	16	66	-	-	PUNCT
dti-2355	16	67	like	like	ADJ
dti-2355	16	68	dots	dot	NOUN
dti-2355	16	69	)	)	PUNCT
dti-2355	16	70	;	;	PUNCT
dti-2355	16	71	and	and	CCONJ
dti-2355	16	72	inverse	inverse	NOUN
dti-2355	16	73	psoriasis	psoriasis	NOUN
dti-2355	16	74	(	(	PUNCT
dti-2355	16	75	affects	affect	VERB
dti-2355	16	76	the	the	DET
dti-2355	16	77	flexure	flexure	NOUN
dti-2355	16	78	surfaces	surface	NOUN
dti-2355	16	79	and	and	CCONJ
dti-2355	16	80	characterized	characterize	VERB
dti-2355	16	81	by	by	ADP
dti-2355	16	82	smooth	smooth	ADJ
dti-2355	16	83	inflamed	inflame	VERB
dti-2355	16	84	lesions	lesion	NOUN
dti-2355	16	85	)	)	PUNCT
dti-2355	16	86	(	(	PUNCT
dti-2355	16	87	1	1	NUM
dti-2355	16	88	)	)	PUNCT
dti-2355	16	89	.	.	PUNCT
dti-2355	17	1	the	the	DET
dti-2355	17	2	pathogenesis	pathogenesis	NOUN
dti-2355	17	3	of	of	ADP
dti-2355	17	4	psoriasis	psoriasis	NOUN
dti-2355	17	5	is	be	AUX
dti-2355	17	6	not	not	PART
dti-2355	17	7	completely	completely	ADV
dti-2355	17	8	understood	understand	VERB
dti-2355	17	9	,	,	PUNCT
dti-2355	17	10	and	and	CCONJ
dti-2355	17	11	the	the	DET
dti-2355	17	12	exact	exact	ADJ
dti-2355	17	13	mechanism	mechanism	NOUN
dti-2355	17	14	remains	remain	VERB
dti-2355	17	15	elusive	elusive	ADJ
dti-2355	17	16	,	,	PUNCT
dti-2355	17	17	although	although	SCONJ
dti-2355	17	18	the	the	DET
dti-2355	17	19	literature	literature	NOUN
dti-2355	17	20	suggests	suggest	VERB
dti-2355	17	21	that	that	SCONJ
dti-2355	17	22	different	different	ADJ
dti-2355	17	23	genetic	genetic	ADJ
dti-2355	17	24	,	,	PUNCT
dti-2355	17	25	epigenetic	epigenetic	ADJ
dti-2355	17	26	,	,	PUNCT
dti-2355	17	27	and	and	CCONJ
dti-2355	17	28	environmental	environmental	ADJ
dti-2355	17	29	factors	factor	NOUN
dti-2355	17	30	may	may	AUX
dti-2355	17	31	be	be	AUX
dti-2355	17	32	responsible	responsible	ADJ
dti-2355	17	33	for	for	ADP
dti-2355	17	34	the	the	DET
dti-2355	17	35	onset	onset	NOUN
dti-2355	17	36	of	of	ADP
dti-2355	17	37	psoriasis	psoriasis	NOUN
dti-2355	17	38	(	(	PUNCT
dti-2355	17	39	2	2	NUM
dti-2355	17	40	)	)	PUNCT
dti-2355	17	41	.	.	PUNCT
dti-2355	18	1	although	although	SCONJ
dti-2355	18	2	not	not	PART
dti-2355	18	3	inherited	inherit	VERB
dti-2355	18	4	in	in	ADP
dti-2355	18	5	a	a	DET
dti-2355	18	6	mendelian	mendelian	ADJ
dti-2355	18	7	fashion	fashion	NOUN
dti-2355	18	8	,	,	PUNCT
dti-2355	18	9	a	a	DET
dti-2355	18	10	familial	familial	ADJ
dti-2355	18	11	predisposition	predisposition	NOUN
dti-2355	18	12	may	may	AUX
dti-2355	18	13	be	be	AUX
dti-2355	18	14	present	present	ADJ
dti-2355	18	15	,	,	PUNCT
dti-2355	18	16	which	which	DET
dti-2355	18	17	significantly	significantly	ADV
dti-2355	18	18	introduction	introduction	NOUN
dti-2355	18	19	psoriasis	psoriasis	NOUN
dti-2355	18	20	is	be	AUX
dti-2355	18	21	an	an	DET
dti-2355	18	22	immune	immune	NOUN
dti-2355	18	23	-	-	PUNCT
dti-2355	18	24	mediated	mediate	VERB
dti-2355	18	25	inflammatory	inflammatory	ADJ
dti-2355	18	26	disease	disease	NOUN
dti-2355	18	27	with	with	ADP
dti-2355	18	28	unknown	unknown	ADJ
dti-2355	18	29	etiology	etiology	NOUN
dti-2355	18	30	,	,	PUNCT
dti-2355	18	31	characterized	characterize	VERB
dti-2355	18	32	by	by	ADP
dti-2355	18	33	the	the	DET
dti-2355	18	34	presence	presence	NOUN
dti-2355	18	35	of	of	ADP
dti-2355	18	36	papules	papule	NOUN
dti-2355	18	37	and	and	CCONJ
dti-2355	18	38	plaques	plaque	NOUN
dti-2355	18	39	of	of	ADP
dti-2355	18	40	various	various	ADJ
dti-2355	18	41	morphology	morphology	NOUN
dti-2355	18	42	and	and	CCONJ
dti-2355	18	43	severity	severity	NOUN
dti-2355	18	44	over	over	ADP
dti-2355	18	45	the	the	DET
dti-2355	18	46	surface	surface	NOUN
dti-2355	18	47	of	of	ADP
dti-2355	18	48	skin	skin	NOUN
dti-2355	18	49	(	(	PUNCT
dti-2355	18	50	1	1	NUM
dti-2355	18	51	)	)	PUNCT
dti-2355	18	52	.	.	PUNCT
dti-2355	19	1	psoriasis	psoriasis	NOUN
dti-2355	19	2	is	be	AUX
dti-2355	19	3	classified	classify	VERB
dti-2355	19	4	as	as	ADP
dti-2355	19	5	an	an	DET
dti-2355	19	6	inflammatory	inflammatory	ADJ
dti-2355	19	7	autoimmune	autoimmune	ADJ
dti-2355	19	8	disease	disease	NOUN
dti-2355	19	9	in	in	ADP
dti-2355	19	10	which	which	PRON
dti-2355	19	11	an	an	DET
dti-2355	19	12	excessively	excessively	ADV
dti-2355	19	13	aberrant	aberrant	ADJ
dti-2355	19	14	hyperproliferation	hyperproliferation	NOUN
dti-2355	19	15	of	of	ADP
dti-2355	19	16	keratinocytes	keratinocyte	NOUN
dti-2355	19	17	is	be	AUX
dti-2355	19	18	present	present	ADJ
dti-2355	19	19	,	,	PUNCT
dti-2355	19	20	along	along	ADP
dti-2355	19	21	with	with	ADP
dti-2355	19	22	dilated	dilated	ADJ
dti-2355	19	23	,	,	PUNCT
dti-2355	19	24	hyperplastic	hyperplastic	ADJ
dti-2355	19	25	blood	blood	NOUN
dti-2355	19	26	vessels	vessel	NOUN
dti-2355	19	27	and	and	CCONJ
dti-2355	19	28	inflammatory	inflammatory	ADJ
dti-2355	19	29	infiltration	infiltration	NOUN
dti-2355	19	30	of	of	ADP
dti-2355	19	31	leukocytes	leukocyte	NOUN
dti-2355	19	32	predominantly	predominantly	ADV
dti-2355	19	33	into	into	ADP
dti-2355	19	34	dermis	dermis	NOUN
dti-2355	19	35	(	(	PUNCT
dti-2355	19	36	2	2	NUM
dti-2355	19	37	)	)	PUNCT
dti-2355	19	38	.	.	PUNCT
dti-2355	20	1	these	these	DET
dti-2355	20	2	features	feature	NOUN
dti-2355	20	3	typically	typically	ADV
dti-2355	20	4	present	present	ADJ
dti-2355	20	5	as	as	ADP
dti-2355	20	6	red	red	ADJ
dti-2355	20	7	skin	skin	NOUN
dti-2355	20	8	patches	patch	NOUN
dti-2355	20	9	that	that	PRON
dti-2355	20	10	are	be	AUX
dti-2355	20	11	itchy	itchy	ADJ
dti-2355	20	12	and	and	CCONJ
dti-2355	20	13	scaly	scaly	NOUN
dti-2355	20	14	.	.	PUNCT
dti-2355	21	1	as	as	ADP
dti-2355	21	2	with	with	ADP
dti-2355	21	3	other	other	ADJ
dti-2355	21	4	autoimmune	autoimmune	ADJ
dti-2355	21	5	diseases	disease	NOUN
dti-2355	21	6	,	,	PUNCT
dti-2355	21	7	psoriasis	psoriasis	NOUN
dti-2355	21	8	may	may	AUX
dti-2355	21	9	have	have	VERB
dti-2355	21	10	a	a	DET
dti-2355	21	11	systemic	systemic	ADJ
dti-2355	21	12	outcome	outcome	NOUN
dti-2355	21	13	beyond	beyond	ADP
dti-2355	21	14	the	the	DET
dti-2355	21	15	skin	skin	NOUN
dti-2355	21	16	,	,	PUNCT
dti-2355	21	17	also	also	ADV
dti-2355	21	18	affecting	affect	VERB
dti-2355	21	19	the	the	DET
dti-2355	21	20	https://doi.org/10.33393/dti.2022.2355	https://doi.org/10.33393/dti.2022.2355	PROPN
dti-2355	21	21	https://creativecommons.org/licenses/by-nc/4.0/legalcode	https://creativecommons.org/licenses/by-nc/4.0/legalcode	NUM
dti-2355	21	22	novel	novel	ADJ
dti-2355	21	23	biologic	biologic	NOUN
dti-2355	21	24	therapy	therapy	NOUN
dti-2355	21	25	for	for	ADP
dti-2355	21	26	psoriasis	psoriasis	NOUN
dti-2355	21	27	management2	management2	NOUN
dti-2355	22	1	©	©	ADP
dti-2355	22	2	2022	2022	NUM
dti-2355	23	1	the	the	DET
dti-2355	23	2	authors	author	NOUN
dti-2355	23	3	.	.	PUNCT
dti-2355	24	1	drug	drug	NOUN
dti-2355	24	2	target	target	NOUN
dti-2355	24	3	insights	insight	NOUN
dti-2355	24	4	issn	issn	VERB
dti-2355	24	5	1177	1177	NUM
dti-2355	24	6	-	-	SYM
dti-2355	24	7	3928	3928	NUM
dti-2355	24	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2355	24	9	increases	increase	VERB
dti-2355	24	10	the	the	DET
dti-2355	24	11	relative	relative	ADJ
dti-2355	24	12	risk	risk	NOUN
dti-2355	24	13	of	of	ADP
dti-2355	24	14	psoriasis	psoriasis	NOUN
dti-2355	24	15	in	in	ADP
dti-2355	24	16	families	family	NOUN
dti-2355	24	17	with	with	ADP
dti-2355	24	18	a	a	DET
dti-2355	24	19	positive	positive	ADJ
dti-2355	24	20	history	history	NOUN
dti-2355	24	21	among	among	ADP
dti-2355	24	22	first	first	ADJ
dti-2355	24	23	-	-	PUNCT
dti-2355	24	24	degree	degree	NOUN
dti-2355	24	25	and	and	CCONJ
dti-2355	24	26	second	second	ADJ
dti-2355	24	27	-	-	PUNCT
dti-2355	24	28	degree	degree	NOUN
dti-2355	24	29	relatives	relative	NOUN
dti-2355	24	30	of	of	ADP
dti-2355	24	31	patients	patient	NOUN
dti-2355	24	32	,	,	PUNCT
dti-2355	24	33	compared	compare	VERB
dti-2355	24	34	to	to	ADP
dti-2355	24	35	the	the	DET
dti-2355	24	36	general	general	ADJ
dti-2355	24	37	population	population	NOUN
dti-2355	24	38	(	(	PUNCT
dti-2355	24	39	2	2	NUM
dti-2355	24	40	)	)	PUNCT
dti-2355	24	41	.	.	PUNCT
dti-2355	25	1	epigenetic	epigenetic	ADJ
dti-2355	25	2	factors	factor	NOUN
dti-2355	25	3	including	include	VERB
dti-2355	25	4	dysregulated	dysregulate	VERB
dti-2355	25	5	deoxyribonucleic	deoxyribonucleic	ADJ
dti-2355	25	6	acid	acid	NOUN
dti-2355	25	7	(	(	PUNCT
dti-2355	25	8	dna	dna	PROPN
dti-2355	25	9	)	)	PUNCT
dti-2355	25	10	methylation	methylation	NOUN
dti-2355	25	11	levels	level	NOUN
dti-2355	25	12	,	,	PUNCT
dti-2355	25	13	abnormal	abnormal	ADJ
dti-2355	25	14	histone	histone	NOUN
dti-2355	25	15	modification	modification	NOUN
dti-2355	25	16	,	,	PUNCT
dti-2355	25	17	and	and	CCONJ
dti-2355	25	18	micro	micro	ADJ
dti-2355	25	19	ribonucleic	ribonucleic	NOUN
dti-2355	25	20	acid	acid	PROPN
dti-2355	25	21	(	(	PUNCT
dti-2355	25	22	mirna	mirna	NOUN
dti-2355	25	23	)	)	PUNCT
dti-2355	25	24	expressions	expression	NOUN
dti-2355	25	25	have	have	AUX
dti-2355	25	26	been	be	AUX
dti-2355	25	27	recognized	recognize	VERB
dti-2355	25	28	as	as	ADP
dti-2355	25	29	crucial	crucial	ADJ
dti-2355	25	30	players	player	NOUN
dti-2355	25	31	in	in	ADP
dti-2355	25	32	the	the	DET
dti-2355	25	33	pathophysiology	pathophysiology	NOUN
dti-2355	25	34	of	of	ADP
dti-2355	25	35	psoriasis	psoriasis	NOUN
dti-2355	25	36	.	.	PUNCT
dti-2355	26	1	among	among	ADP
dti-2355	26	2	other	other	ADJ
dti-2355	26	3	factors	factor	NOUN
dti-2355	26	4	,	,	PUNCT
dti-2355	26	5	excessive	excessive	ADJ
dti-2355	26	6	activation	activation	NOUN
dti-2355	26	7	of	of	ADP
dti-2355	26	8	the	the	DET
dti-2355	26	9	adaptive	adaptive	ADJ
dti-2355	26	10	immune	immune	ADJ
dti-2355	26	11	system	system	NOUN
dti-2355	26	12	and	and	CCONJ
dti-2355	26	13	the	the	DET
dti-2355	26	14	interplay	interplay	NOUN
dti-2355	26	15	of	of	ADP
dti-2355	26	16	immune	immune	ADJ
dti-2355	26	17	cells	cell	NOUN
dti-2355	26	18	and	and	CCONJ
dti-2355	26	19	cytokines	cytokine	NOUN
dti-2355	26	20	are	be	AUX
dti-2355	26	21	thought	think	VERB
dti-2355	26	22	to	to	PART
dti-2355	26	23	play	play	VERB
dti-2355	26	24	a	a	DET
dti-2355	26	25	role	role	NOUN
dti-2355	26	26	in	in	ADP
dti-2355	26	27	the	the	DET
dti-2355	26	28	onset	onset	NOUN
dti-2355	26	29	of	of	ADP
dti-2355	26	30	psoriasis	psoriasis	NOUN
dti-2355	26	31	(	(	PUNCT
dti-2355	26	32	2,3	2,3	NUM
dti-2355	26	33	)	)	PUNCT
dti-2355	26	34	.	.	PUNCT
dti-2355	27	1	an	an	DET
dti-2355	27	2	initial	initial	ADJ
dti-2355	27	3	secretion	secretion	NOUN
dti-2355	27	4	of	of	ADP
dti-2355	27	5	cytokines	cytokine	NOUN
dti-2355	27	6	that	that	PRON
dti-2355	27	7	activate	activate	VERB
dti-2355	27	8	myeloid	myeloid	ADJ
dti-2355	27	9	dendritic	dendritic	ADJ
dti-2355	27	10	cells	cell	NOUN
dti-2355	27	11	,	,	PUNCT
dti-2355	27	12	from	from	ADP
dti-2355	27	13	plasmacytoid	plasmacytoid	NOUN
dti-2355	27	14	dendritic	dendritic	ADJ
dti-2355	27	15	cells	cell	NOUN
dti-2355	27	16	,	,	PUNCT
dti-2355	27	17	keratinocytes	keratinocyte	NOUN
dti-2355	27	18	,	,	PUNCT
dti-2355	27	19	natural	natural	ADJ
dti-2355	27	20	killer	killer	NOUN
dti-2355	27	21	t	t	NOUN
dti-2355	27	22	cells	cell	NOUN
dti-2355	27	23	,	,	PUNCT
dti-2355	27	24	and	and	CCONJ
dti-2355	27	25	macrophages	macrophage	NOUN
dti-2355	27	26	,	,	PUNCT
dti-2355	27	27	is	be	AUX
dti-2355	27	28	thought	think	VERB
dti-2355	27	29	to	to	PART
dti-2355	27	30	initiate	initiate	VERB
dti-2355	27	31	the	the	DET
dti-2355	27	32	first	first	ADJ
dti-2355	27	33	steps	step	NOUN
dti-2355	27	34	of	of	ADP
dti-2355	27	35	the	the	DET
dti-2355	27	36	pathogenesis	pathogenesis	NOUN
dti-2355	27	37	of	of	ADP
dti-2355	27	38	psoriasis	psoriasis	NOUN
dti-2355	27	39	(	(	PUNCT
dti-2355	27	40	3	3	NUM
dti-2355	27	41	)	)	PUNCT
dti-2355	27	42	.	.	PUNCT
dti-2355	28	1	erythrodermic	erythrodermic	ADJ
dti-2355	28	2	psoriasis	psoriasis	NOUN
dti-2355	28	3	among	among	ADP
dti-2355	28	4	the	the	DET
dti-2355	28	5	other	other	ADJ
dti-2355	28	6	forms	form	NOUN
dti-2355	28	7	of	of	ADP
dti-2355	28	8	psoriasis	psoriasis	NOUN
dti-2355	28	9	,	,	PUNCT
dti-2355	28	10	ep	ep	PROPN
dti-2355	28	11	represents	represent	VERB
dti-2355	28	12	a	a	DET
dti-2355	28	13	rare	rare	ADJ
dti-2355	28	14	and	and	CCONJ
dti-2355	28	15	severe	severe	ADJ
dti-2355	28	16	form	form	NOUN
dti-2355	28	17	that	that	PRON
dti-2355	28	18	affects	affect	VERB
dti-2355	28	19	1	1	NUM
dti-2355	28	20	%	%	NOUN
dti-2355	28	21	to	to	PART
dti-2355	28	22	2.25	2.25	NUM
dti-2355	28	23	%	%	NOUN
dti-2355	28	24	of	of	ADP
dti-2355	28	25	patients	patient	NOUN
dti-2355	28	26	with	with	ADP
dti-2355	28	27	psoriasis	psoriasis	NOUN
dti-2355	28	28	.	.	PUNCT
dti-2355	29	1	the	the	DET
dti-2355	29	2	clinical	clinical	ADJ
dti-2355	29	3	characteristics	characteristic	NOUN
dti-2355	29	4	of	of	ADP
dti-2355	29	5	this	this	DET
dti-2355	29	6	form	form	NOUN
dti-2355	29	7	of	of	ADP
dti-2355	29	8	psoriasis	psoriasis	NOUN
dti-2355	29	9	are	be	AUX
dti-2355	29	10	the	the	DET
dti-2355	29	11	presence	presence	NOUN
dti-2355	29	12	of	of	ADP
dti-2355	29	13	erythematous	erythematous	ADJ
dti-2355	29	14	,	,	PUNCT
dti-2355	29	15	edematous	edematous	ADJ
dti-2355	29	16	,	,	PUNCT
dti-2355	29	17	often	often	ADV
dti-2355	29	18	exfoliative	exfoliative	ADJ
dti-2355	29	19	lesions	lesion	NOUN
dti-2355	29	20	that	that	PRON
dti-2355	29	21	affect	affect	VERB
dti-2355	29	22	over	over	ADP
dti-2355	29	23	75	75	NUM
dti-2355	29	24	%	%	NOUN
dti-2355	29	25	of	of	ADP
dti-2355	29	26	the	the	DET
dti-2355	29	27	body	body	NOUN
dti-2355	29	28	surface	surface	NOUN
dti-2355	29	29	area	area	NOUN
dti-2355	29	30	(	(	PUNCT
dti-2355	29	31	4	4	NUM
dti-2355	29	32	)	)	PUNCT
dti-2355	29	33	,	,	PUNCT
dti-2355	29	34	and	and	CCONJ
dti-2355	29	35	are	be	AUX
dti-2355	29	36	often	often	ADV
dti-2355	29	37	associated	associate	VERB
dti-2355	29	38	with	with	ADP
dti-2355	29	39	numerous	numerous	ADJ
dti-2355	29	40	systemic	systemic	ADJ
dti-2355	29	41	symptoms	symptom	NOUN
dti-2355	29	42	such	such	ADJ
dti-2355	29	43	as	as	ADP
dti-2355	29	44	fever	fever	NOUN
dti-2355	29	45	,	,	PUNCT
dti-2355	29	46	tachycardia	tachycardia	NOUN
dti-2355	29	47	,	,	PUNCT
dti-2355	29	48	lymphadenopathy	lymphadenopathy	ADJ
dti-2355	29	49	,	,	PUNCT
dti-2355	29	50	arthralgia	arthralgia	NOUN
dti-2355	29	51	,	,	PUNCT
dti-2355	29	52	and	and	CCONJ
dti-2355	29	53	fatigue	fatigue	NOUN
dti-2355	29	54	(	(	PUNCT
dti-2355	29	55	5	5	NUM
dti-2355	29	56	)	)	PUNCT
dti-2355	29	57	.	.	PUNCT
dti-2355	30	1	there	there	PRON
dti-2355	30	2	is	be	VERB
dti-2355	30	3	a	a	DET
dti-2355	30	4	substantial	substantial	ADJ
dti-2355	30	5	risk	risk	NOUN
dti-2355	30	6	of	of	ADP
dti-2355	30	7	mortality	mortality	NOUN
dti-2355	30	8	due	due	ADP
dti-2355	30	9	to	to	ADP
dti-2355	30	10	transepidermal	transepidermal	ADJ
dti-2355	30	11	fluid	fluid	NOUN
dti-2355	30	12	and	and	CCONJ
dti-2355	30	13	nutrient	nutrient	NOUN
dti-2355	30	14	loss	loss	NOUN
dti-2355	30	15	,	,	PUNCT
dti-2355	30	16	and	and	CCONJ
dti-2355	30	17	which	which	PRON
dti-2355	30	18	in	in	ADP
dti-2355	30	19	severe	severe	ADJ
dti-2355	30	20	cases	case	NOUN
dti-2355	30	21	may	may	AUX
dti-2355	30	22	lead	lead	VERB
dti-2355	30	23	to	to	ADP
dti-2355	30	24	multiorgan	multiorgan	NOUN
dti-2355	30	25	failure	failure	NOUN
dti-2355	30	26	and	and	CCONJ
dti-2355	30	27	death	death	NOUN
dti-2355	30	28	(	(	PUNCT
dti-2355	30	29	4	4	NUM
dti-2355	30	30	)	)	PUNCT
dti-2355	30	31	.	.	PUNCT
dti-2355	31	1	ep	ep	PROPN
dti-2355	31	2	generally	generally	ADV
dti-2355	31	3	develops	develop	VERB
dti-2355	31	4	in	in	ADP
dti-2355	31	5	patients	patient	NOUN
dti-2355	31	6	with	with	ADP
dti-2355	31	7	poorly	poorly	ADV
dti-2355	31	8	controlled	control	VERB
dti-2355	31	9	psoriasis	psoriasis	NOUN
dti-2355	31	10	and	and	CCONJ
dti-2355	31	11	as	as	ADP
dti-2355	31	12	a	a	DET
dti-2355	31	13	result	result	NOUN
dti-2355	31	14	of	of	ADP
dti-2355	31	15	the	the	DET
dti-2355	31	16	abrupt	abrupt	ADJ
dti-2355	31	17	withdrawal	withdrawal	NOUN
dti-2355	31	18	of	of	ADP
dti-2355	31	19	systemic	systemic	ADJ
dti-2355	31	20	medications	medication	NOUN
dti-2355	31	21	such	such	ADJ
dti-2355	31	22	as	as	ADP
dti-2355	31	23	corticosteroids	corticosteroid	NOUN
dti-2355	31	24	,	,	PUNCT
dti-2355	31	25	drug	drug	NOUN
dti-2355	31	26	reactions	reaction	NOUN
dti-2355	31	27	to	to	ADP
dti-2355	31	28	medications	medication	NOUN
dti-2355	31	29	such	such	ADJ
dti-2355	31	30	as	as	ADP
dti-2355	31	31	lithium	lithium	NOUN
dti-2355	31	32	,	,	PUNCT
dti-2355	31	33	and	and	CCONJ
dti-2355	31	34	underlying	underlying	ADJ
dti-2355	31	35	systemic	systemic	ADJ
dti-2355	31	36	infections	infection	NOUN
dti-2355	31	37	(	(	PUNCT
dti-2355	31	38	5	5	NUM
dti-2355	31	39	)	)	PUNCT
dti-2355	31	40	.	.	PUNCT
dti-2355	32	1	for	for	ADP
dti-2355	32	2	a	a	DET
dti-2355	32	3	clear	clear	ADJ
dti-2355	32	4	and	and	CCONJ
dti-2355	32	5	correct	correct	ADJ
dti-2355	32	6	diagnosis	diagnosis	NOUN
dti-2355	32	7	of	of	ADP
dti-2355	32	8	ep	ep	PROPN
dti-2355	32	9	,	,	PUNCT
dti-2355	32	10	two	two	NUM
dti-2355	32	11	general	general	ADJ
dti-2355	32	12	clinical	clinical	ADJ
dti-2355	32	13	subtypes	subtype	NOUN
dti-2355	32	14	that	that	PRON
dti-2355	32	15	define	define	VERB
dti-2355	32	16	the	the	DET
dti-2355	32	17	disease	disease	NOUN
dti-2355	32	18	must	must	AUX
dti-2355	32	19	be	be	AUX
dti-2355	32	20	considered	consider	VERB
dti-2355	32	21	.	.	PUNCT
dti-2355	33	1	the	the	DET
dti-2355	33	2	first	first	ADJ
dti-2355	33	3	subtype	subtype	NOUN
dti-2355	33	4	is	be	AUX
dti-2355	33	5	characterized	characterize	VERB
dti-2355	33	6	by	by	ADP
dti-2355	33	7	psoriatic	psoriatic	ADJ
dti-2355	33	8	plaques	plaque	NOUN
dti-2355	33	9	that	that	PRON
dti-2355	33	10	gradually	gradually	ADV
dti-2355	33	11	differentiate	differentiate	VERB
dti-2355	33	12	and	and	CCONJ
dti-2355	33	13	develop	develop	VERB
dti-2355	33	14	into	into	ADP
dti-2355	33	15	generalized	generalized	ADJ
dti-2355	33	16	erythroderma	erythroderma	NOUN
dti-2355	33	17	,	,	PUNCT
dti-2355	33	18	although	although	SCONJ
dti-2355	33	19	,	,	PUNCT
dti-2355	33	20	overall	overall	ADV
dti-2355	33	21	,	,	PUNCT
dti-2355	33	22	the	the	DET
dti-2355	33	23	plaques	plaque	NOUN
dti-2355	33	24	remain	remain	VERB
dti-2355	33	25	differentiable	differentiable	ADJ
dti-2355	33	26	from	from	ADP
dti-2355	33	27	the	the	DET
dti-2355	33	28	erythroderma	erythroderma	NOUN
dti-2355	33	29	.	.	PUNCT
dti-2355	34	1	this	this	DET
dti-2355	34	2	form	form	NOUN
dti-2355	34	3	of	of	ADP
dti-2355	34	4	ep	ep	PROPN
dti-2355	34	5	has	have	VERB
dti-2355	34	6	a	a	DET
dti-2355	34	7	stable	stable	ADJ
dti-2355	34	8	course	course	NOUN
dti-2355	34	9	and	and	CCONJ
dti-2355	34	10	a	a	DET
dti-2355	34	11	good	good	ADJ
dti-2355	34	12	prognosis	prognosis	NOUN
dti-2355	34	13	.	.	PUNCT
dti-2355	35	1	in	in	ADP
dti-2355	35	2	contrast	contrast	NOUN
dti-2355	35	3	,	,	PUNCT
dti-2355	35	4	the	the	DET
dti-2355	35	5	second	second	ADJ
dti-2355	35	6	ep	ep	NOUN
dti-2355	35	7	subtype	subtype	NOUN
dti-2355	35	8	is	be	AUX
dti-2355	35	9	more	more	ADV
dti-2355	35	10	common	common	ADJ
dti-2355	35	11	in	in	ADP
dti-2355	35	12	a	a	DET
dti-2355	35	13	psoriatic	psoriatic	ADJ
dti-2355	35	14	arthritis	arthritis	NOUN
dti-2355	35	15	setting	setting	NOUN
dti-2355	35	16	and	and	CCONJ
dti-2355	35	17	plaques	plaque	NOUN
dti-2355	35	18	usually	usually	ADV
dti-2355	35	19	can	can	AUX
dti-2355	35	20	not	not	PART
dti-2355	35	21	be	be	AUX
dti-2355	35	22	distinguishable	distinguishable	ADJ
dti-2355	35	23	from	from	ADP
dti-2355	35	24	whole	whole	ADJ
dti-2355	35	25	-	-	PUNCT
dti-2355	35	26	body	body	NOUN
dti-2355	35	27	erythema	erythema	NOUN
dti-2355	35	28	(	(	PUNCT
dti-2355	35	29	6	6	NUM
dti-2355	35	30	)	)	PUNCT
dti-2355	35	31	.	.	PUNCT
dti-2355	36	1	as	as	ADP
dti-2355	36	2	with	with	ADP
dti-2355	36	3	psoriasis	psoriasis	NOUN
dti-2355	36	4	,	,	PUNCT
dti-2355	36	5	the	the	DET
dti-2355	36	6	exact	exact	ADJ
dti-2355	36	7	pathogenesis	pathogenesis	NOUN
dti-2355	36	8	of	of	ADP
dti-2355	36	9	ep	ep	PROPN
dti-2355	36	10	is	be	AUX
dti-2355	36	11	not	not	PART
dti-2355	36	12	fully	fully	ADV
dti-2355	36	13	clarified	clarify	VERB
dti-2355	36	14	.	.	PUNCT
dti-2355	37	1	the	the	DET
dti-2355	37	2	current	current	ADJ
dti-2355	37	3	literature	literature	NOUN
dti-2355	37	4	suggests	suggest	VERB
dti-2355	37	5	the	the	DET
dti-2355	37	6	involvement	involvement	NOUN
dti-2355	37	7	of	of	ADP
dti-2355	37	8	an	an	DET
dti-2355	37	9	unbalanced	unbalanced	ADJ
dti-2355	37	10	t	t	NOUN
dti-2355	37	11	-	-	PUNCT
dti-2355	37	12	helper	helper	NOUN
dti-2355	37	13	(	(	PUNCT
dti-2355	37	14	th)1	th)1	PROPN
dti-2355	37	15	/	/	SYM
dti-2355	37	16	th2	th2	PROPN
dti-2355	37	17	differentiation	differentiation	NOUN
dti-2355	37	18	in	in	ADP
dti-2355	37	19	favor	favor	NOUN
dti-2355	37	20	of	of	ADP
dti-2355	37	21	the	the	DET
dti-2355	37	22	th2	th2	PROPN
dti-2355	37	23	phenotype	phenotype	NOUN
dti-2355	37	24	and	and	CCONJ
dti-2355	37	25	its	its	PRON
dti-2355	37	26	related	related	ADJ
dti-2355	37	27	cytokine	cytokine	NOUN
dti-2355	37	28	secretion	secretion	NOUN
dti-2355	37	29	.	.	PUNCT
dti-2355	38	1	interleukin	interleukin	NOUN
dti-2355	38	2	(	(	PUNCT
dti-2355	38	3	il)-4	il)-4	NOUN
dti-2355	38	4	and	and	CCONJ
dti-2355	38	5	il-13	il-13	X
dti-2355	38	6	,	,	PUNCT
dti-2355	38	7	in	in	ADP
dti-2355	38	8	particular	particular	ADJ
dti-2355	38	9	,	,	PUNCT
dti-2355	38	10	have	have	AUX
dti-2355	38	11	been	be	AUX
dti-2355	38	12	shown	show	VERB
dti-2355	38	13	to	to	PART
dti-2355	38	14	be	be	AUX
dti-2355	38	15	elevated	elevate	VERB
dti-2355	38	16	in	in	ADP
dti-2355	38	17	ep	ep	PROPN
dti-2355	38	18	relative	relative	ADJ
dti-2355	38	19	to	to	ADP
dti-2355	38	20	both	both	DET
dti-2355	38	21	psoriasis	psoriasis	NOUN
dti-2355	38	22	patients	patient	NOUN
dti-2355	38	23	and	and	CCONJ
dti-2355	38	24	healthy	healthy	ADJ
dti-2355	38	25	controls	control	NOUN
dti-2355	38	26	.	.	PUNCT
dti-2355	39	1	several	several	ADJ
dti-2355	39	2	studies	study	NOUN
dti-2355	39	3	have	have	AUX
dti-2355	39	4	demonstrated	demonstrate	VERB
dti-2355	39	5	that	that	SCONJ
dti-2355	39	6	anti	anti	ADJ
dti-2355	39	7	–	–	ADJ
dti-2355	39	8	tumor	tumor	ADJ
dti-2355	39	9	necrosis	necrosis	NOUN
dti-2355	39	10	factor	factor	NOUN
dti-2355	39	11	(	(	PUNCT
dti-2355	39	12	tnf)-α	tnf)-α	PROPN
dti-2355	39	13	agents	agent	NOUN
dti-2355	39	14	improve	improve	VERB
dti-2355	39	15	ep	ep	PROPN
dti-2355	39	16	outcomes	outcome	NOUN
dti-2355	39	17	,	,	PUNCT
dti-2355	39	18	suggesting	suggest	VERB
dti-2355	39	19	that	that	SCONJ
dti-2355	39	20	tnf	tnf	PROPN
dti-2355	39	21	-	-	PUNCT
dti-2355	39	22	α	α	PROPN
dti-2355	39	23	may	may	AUX
dti-2355	39	24	play	play	VERB
dti-2355	39	25	a	a	DET
dti-2355	39	26	role	role	NOUN
dti-2355	39	27	in	in	ADP
dti-2355	39	28	the	the	DET
dti-2355	39	29	pathogenesis	pathogenesis	NOUN
dti-2355	39	30	of	of	ADP
dti-2355	39	31	ep	ep	PROPN
dti-2355	39	32	(	(	PUNCT
dti-2355	39	33	6	6	NUM
dti-2355	39	34	)	)	PUNCT
dti-2355	39	35	.	.	PUNCT
dti-2355	40	1	although	although	SCONJ
dti-2355	40	2	difficult	difficult	ADJ
dti-2355	40	3	and	and	CCONJ
dti-2355	40	4	challenging	challenging	ADJ
dti-2355	40	5	,	,	PUNCT
dti-2355	40	6	the	the	DET
dti-2355	40	7	management	management	NOUN
dti-2355	40	8	of	of	ADP
dti-2355	40	9	ep	ep	PROPN
dti-2355	40	10	is	be	AUX
dti-2355	40	11	possible	possible	ADJ
dti-2355	40	12	through	through	ADP
dti-2355	40	13	several	several	ADJ
dti-2355	40	14	treatment	treatment	NOUN
dti-2355	40	15	options	option	NOUN
dti-2355	40	16	.	.	PUNCT
dti-2355	41	1	the	the	DET
dti-2355	41	2	us	us	PROPN
dti-2355	41	3	national	national	PROPN
dti-2355	41	4	psoriasis	psoriasis	NOUN
dti-2355	41	5	foundation	foundation	NOUN
dti-2355	41	6	had	have	AUX
dti-2355	41	7	suggested	suggest	VERB
dti-2355	41	8	,	,	PUNCT
dti-2355	41	9	in	in	ADP
dti-2355	41	10	2010	2010	NUM
dti-2355	41	11	in	in	ADP
dti-2355	41	12	their	their	PRON
dti-2355	41	13	consensus	consensus	NOUN
dti-2355	41	14	guidelines	guideline	NOUN
dti-2355	41	15	,	,	PUNCT
dti-2355	41	16	the	the	DET
dti-2355	41	17	use	use	NOUN
dti-2355	41	18	of	of	ADP
dti-2355	41	19	cyclosporine	cyclosporine	NOUN
dti-2355	41	20	or	or	CCONJ
dti-2355	41	21	infliximab	infliximab	NOUN
dti-2355	41	22	as	as	ADP
dti-2355	41	23	first	first	ADJ
dti-2355	41	24	-	-	PUNCT
dti-2355	41	25	line	line	NOUN
dti-2355	41	26	therapy	therapy	NOUN
dti-2355	41	27	in	in	ADP
dti-2355	41	28	unstable	unstable	ADJ
dti-2355	41	29	cases	case	NOUN
dti-2355	41	30	,	,	PUNCT
dti-2355	41	31	with	with	ADP
dti-2355	41	32	acitretin	acitretin	NOUN
dti-2355	41	33	and	and	CCONJ
dti-2355	41	34	methotrexate	methotrexate	NOUN
dti-2355	41	35	reserved	reserve	VERB
dti-2355	41	36	for	for	ADP
dti-2355	41	37	more	more	ADV
dti-2355	41	38	stable	stable	ADJ
dti-2355	41	39	cases	case	NOUN
dti-2355	41	40	.	.	PUNCT
dti-2355	42	1	since	since	SCONJ
dti-2355	42	2	then	then	ADV
dti-2355	42	3	,	,	PUNCT
dti-2355	42	4	other	other	ADJ
dti-2355	42	5	therapies	therapy	NOUN
dti-2355	42	6	and	and	CCONJ
dti-2355	42	7	treatment	treatment	NOUN
dti-2355	42	8	strategies	strategy	NOUN
dti-2355	42	9	have	have	AUX
dti-2355	42	10	emerged	emerge	VERB
dti-2355	42	11	,	,	PUNCT
dti-2355	42	12	including	include	VERB
dti-2355	42	13	topical	topical	ADJ
dti-2355	42	14	treatment	treatment	NOUN
dti-2355	42	15	with	with	ADP
dti-2355	42	16	steroids	steroid	NOUN
dti-2355	42	17	and	and	CCONJ
dti-2355	42	18	vitamin	vitamin	NOUN
dti-2355	42	19	d	d	NOUN
dti-2355	42	20	analogues	analogue	NOUN
dti-2355	42	21	,	,	PUNCT
dti-2355	42	22	as	as	ADV
dti-2355	42	23	well	well	ADV
dti-2355	42	24	as	as	ADP
dti-2355	42	25	phototherapy	phototherapy	NOUN
dti-2355	42	26	.	.	PUNCT
dti-2355	43	1	other	other	ADJ
dti-2355	43	2	studies	study	NOUN
dti-2355	43	3	have	have	AUX
dti-2355	43	4	also	also	ADV
dti-2355	43	5	demonstrated	demonstrate	VERB
dti-2355	43	6	the	the	DET
dti-2355	43	7	efficacy	efficacy	NOUN
dti-2355	43	8	of	of	ADP
dti-2355	43	9	systemic	systemic	ADJ
dti-2355	43	10	agents	agent	NOUN
dti-2355	43	11	,	,	PUNCT
dti-2355	43	12	including	include	VERB
dti-2355	43	13	second	second	ADJ
dti-2355	43	14	-	-	PUNCT
dti-2355	43	15	generation	generation	NOUN
dti-2355	43	16	retinoids	retinoid	NOUN
dti-2355	43	17	(	(	PUNCT
dti-2355	43	18	acitretin	acitretin	NOUN
dti-2355	43	19	)	)	PUNCT
dti-2355	43	20	and	and	CCONJ
dti-2355	43	21	immunosuppressive	immunosuppressive	ADJ
dti-2355	43	22	drugs	drug	NOUN
dti-2355	43	23	(	(	PUNCT
dti-2355	43	24	methotrexate	methotrexate	NOUN
dti-2355	43	25	and	and	CCONJ
dti-2355	43	26	cyclosporine	cyclosporine	NOUN
dti-2355	43	27	)	)	PUNCT
dti-2355	43	28	,	,	PUNCT
dti-2355	43	29	which	which	PRON
dti-2355	43	30	showed	show	VERB
dti-2355	43	31	complete	complete	ADJ
dti-2355	43	32	remission	remission	NOUN
dti-2355	43	33	and	and	CCONJ
dti-2355	43	34	significant	significant	ADJ
dti-2355	43	35	improvement	improvement	NOUN
dti-2355	43	36	in	in	ADP
dti-2355	43	37	ep	ep	PROPN
dti-2355	43	38	outcomes	outcome	NOUN
dti-2355	43	39	.	.	PUNCT
dti-2355	44	1	recently	recently	ADV
dti-2355	44	2	,	,	PUNCT
dti-2355	44	3	another	another	DET
dti-2355	44	4	class	class	NOUN
dti-2355	44	5	of	of	ADP
dti-2355	44	6	drugs	drug	NOUN
dti-2355	44	7	,	,	PUNCT
dti-2355	44	8	called	call	VERB
dti-2355	44	9	biological	biological	ADJ
dti-2355	44	10	agents	agent	NOUN
dti-2355	44	11	,	,	PUNCT
dti-2355	44	12	has	have	AUX
dti-2355	44	13	demonstrated	demonstrate	VERB
dti-2355	44	14	high	high	ADJ
dti-2355	44	15	efficacy	efficacy	NOUN
dti-2355	44	16	in	in	ADP
dti-2355	44	17	ep	ep	PROPN
dti-2355	44	18	management	management	NOUN
dti-2355	44	19	.	.	PUNCT
dti-2355	45	1	biological	biological	ADJ
dti-2355	45	2	therapies	therapy	NOUN
dti-2355	45	3	represent	represent	VERB
dti-2355	45	4	an	an	DET
dti-2355	45	5	emerging	emerge	VERB
dti-2355	45	6	class	class	NOUN
dti-2355	45	7	of	of	ADP
dti-2355	45	8	immunosuppressive	immunosuppressive	ADJ
dti-2355	45	9	drugs	drug	NOUN
dti-2355	45	10	,	,	PUNCT
dti-2355	45	11	which	which	PRON
dti-2355	45	12	,	,	PUNCT
dti-2355	45	13	thanks	thank	NOUN
dti-2355	45	14	to	to	ADP
dti-2355	45	15	their	their	PRON
dti-2355	45	16	enhanced	enhanced	ADJ
dti-2355	45	17	selectivity	selectivity	NOUN
dti-2355	45	18	to	to	ADP
dti-2355	45	19	specific	specific	ADJ
dti-2355	45	20	cytokines	cytokine	NOUN
dti-2355	45	21	,	,	PUNCT
dti-2355	45	22	may	may	AUX
dti-2355	45	23	represent	represent	VERB
dti-2355	45	24	a	a	DET
dti-2355	45	25	valid	valid	ADJ
dti-2355	45	26	alternative	alternative	NOUN
dti-2355	45	27	to	to	ADP
dti-2355	45	28	the	the	DET
dti-2355	45	29	canonical	canonical	ADJ
dti-2355	45	30	treatments	treatment	NOUN
dti-2355	45	31	.	.	PUNCT
dti-2355	46	1	biological	biological	ADJ
dti-2355	46	2	therapies	therapy	NOUN
dti-2355	46	3	include	include	VERB
dti-2355	46	4	tnf	tnf	PROPN
dti-2355	46	5	-	-	PUNCT
dti-2355	46	6	α	α	NOUN
dti-2355	46	7	inhibitors	inhibitor	NOUN
dti-2355	46	8	,	,	PUNCT
dti-2355	46	9	il-12/23	il-12/23	ADJ
dti-2355	46	10	inhibitors	inhibitor	NOUN
dti-2355	46	11	,	,	PUNCT
dti-2355	46	12	and	and	CCONJ
dti-2355	46	13	il-17	il-17	ADV
dti-2355	46	14	inhibitors	inhibitor	NOUN
dti-2355	46	15	(	(	PUNCT
dti-2355	46	16	6	6	NUM
dti-2355	46	17	)	)	PUNCT
dti-2355	46	18	.	.	PUNCT
dti-2355	47	1	secukinumab	secukinumab	NOUN
dti-2355	47	2	:	:	PUNCT
dti-2355	47	3	drug	drug	NOUN
dti-2355	47	4	description	description	NOUN
dti-2355	47	5	and	and	CCONJ
dti-2355	47	6	focus	focus	VERB
dti-2355	47	7	on	on	ADP
dti-2355	47	8	the	the	DET
dti-2355	47	9	treatment	treatment	NOUN
dti-2355	47	10	of	of	ADP
dti-2355	47	11	ep	ep	PROPN
dti-2355	47	12	as	as	SCONJ
dti-2355	47	13	mentioned	mention	VERB
dti-2355	47	14	,	,	PUNCT
dti-2355	47	15	an	an	DET
dti-2355	47	16	unbalanced	unbalanced	ADJ
dti-2355	47	17	proinflammatory	proinflammatory	ADJ
dti-2355	47	18	response	response	NOUN
dti-2355	47	19	and	and	CCONJ
dti-2355	47	20	massive	massive	ADJ
dti-2355	47	21	cytokine	cytokine	NOUN
dti-2355	47	22	secretion	secretion	NOUN
dti-2355	47	23	may	may	AUX
dti-2355	47	24	promote	promote	VERB
dti-2355	47	25	and	and	CCONJ
dti-2355	47	26	sustain	sustain	VERB
dti-2355	47	27	worsening	worsen	VERB
dti-2355	47	28	symptoms	symptom	NOUN
dti-2355	47	29	of	of	ADP
dti-2355	47	30	ep	ep	PROPN
dti-2355	47	31	.	.	PUNCT
dti-2355	48	1	besides	besides	SCONJ
dti-2355	48	2	th1	th1	PROPN
dti-2355	48	3	and	and	CCONJ
dti-2355	48	4	th2	th2	PROPN
dti-2355	48	5	,	,	PUNCT
dti-2355	48	6	the	the	DET
dti-2355	48	7	recent	recent	ADJ
dti-2355	48	8	discovery	discovery	NOUN
dti-2355	48	9	of	of	ADP
dti-2355	48	10	the	the	DET
dti-2355	48	11	new	new	ADJ
dti-2355	48	12	class	class	NOUN
dti-2355	48	13	of	of	ADP
dti-2355	48	14	t	t	PROPN
dti-2355	48	15	-	-	PUNCT
dti-2355	48	16	helper	helper	NOUN
dti-2355	48	17	cells	cell	NOUN
dti-2355	48	18	,	,	PUNCT
dti-2355	48	19	th17	th17	PROPN
dti-2355	48	20	,	,	PUNCT
dti-2355	48	21	also	also	ADV
dti-2355	48	22	highlighted	highlight	VERB
dti-2355	48	23	the	the	DET
dti-2355	48	24	possible	possible	ADJ
dti-2355	48	25	role	role	NOUN
dti-2355	48	26	of	of	ADP
dti-2355	48	27	the	the	DET
dti-2355	48	28	proinflammatory	proinflammatory	ADJ
dti-2355	48	29	cytokine	cytokine	NOUN
dti-2355	48	30	il-17	il-17	ADP
dti-2355	48	31	(	(	PUNCT
dti-2355	48	32	secreted	secrete	VERB
dti-2355	48	33	by	by	ADP
dti-2355	48	34	th17	th17	NOUN
dti-2355	48	35	)	)	PUNCT
dti-2355	48	36	in	in	ADP
dti-2355	48	37	the	the	DET
dti-2355	48	38	pathogenesis	pathogenesis	NOUN
dti-2355	48	39	of	of	ADP
dti-2355	48	40	ep	ep	PROPN
dti-2355	48	41	(	(	PUNCT
dti-2355	48	42	7	7	NUM
dti-2355	48	43	)	)	PUNCT
dti-2355	48	44	.	.	PUNCT
dti-2355	49	1	some	some	DET
dti-2355	49	2	environmental	environmental	ADJ
dti-2355	49	3	triggers	trigger	NOUN
dti-2355	49	4	,	,	PUNCT
dti-2355	49	5	such	such	ADJ
dti-2355	49	6	as	as	ADP
dti-2355	49	7	physical	physical	ADJ
dti-2355	49	8	trauma	trauma	NOUN
dti-2355	49	9	,	,	PUNCT
dti-2355	49	10	drugs	drug	NOUN
dti-2355	49	11	,	,	PUNCT
dti-2355	49	12	or	or	CCONJ
dti-2355	49	13	infections	infection	NOUN
dti-2355	49	14	,	,	PUNCT
dti-2355	49	15	release	release	VERB
dti-2355	49	16	proinflammatory	proinflammatory	ADJ
dti-2355	49	17	cytokines	cytokine	NOUN
dti-2355	49	18	,	,	PUNCT
dti-2355	49	19	including	include	VERB
dti-2355	49	20	il-23	il-23	ADJ
dti-2355	49	21	and	and	CCONJ
dti-2355	49	22	tnf	tnf	PROPN
dti-2355	49	23	-	-	PUNCT
dti-2355	49	24	α	α	PROPN
dti-2355	49	25	.	.	PUNCT
dti-2355	50	1	differentiation	differentiation	NOUN
dti-2355	50	2	of	of	ADP
dti-2355	50	3	t	t	PROPN
dti-2355	50	4	helper	helper	NOUN
dti-2355	50	5	into	into	ADP
dti-2355	50	6	th17	th17	PROPN
dti-2355	50	7	cells	cell	NOUN
dti-2355	50	8	and	and	CCONJ
dti-2355	50	9	the	the	DET
dti-2355	50	10	release	release	NOUN
dti-2355	50	11	of	of	ADP
dti-2355	50	12	cytokines	cytokine	NOUN
dti-2355	50	13	,	,	PUNCT
dti-2355	50	14	such	such	ADJ
dti-2355	50	15	as	as	ADP
dti-2355	50	16	il-17	il-17	NOUN
dti-2355	50	17	,	,	PUNCT
dti-2355	50	18	promote	promote	VERB
dti-2355	50	19	keratinocyte	keratinocyte	NOUN
dti-2355	50	20	proliferation	proliferation	NOUN
dti-2355	50	21	,	,	PUNCT
dti-2355	50	22	which	which	PRON
dti-2355	50	23	,	,	PUNCT
dti-2355	50	24	in	in	ADP
dti-2355	50	25	the	the	DET
dti-2355	50	26	setting	setting	NOUN
dti-2355	50	27	of	of	ADP
dti-2355	50	28	ep	ep	NOUN
dti-2355	50	29	,	,	PUNCT
dti-2355	50	30	also	also	ADV
dti-2355	50	31	release	release	VERB
dti-2355	50	32	additional	additional	ADJ
dti-2355	50	33	ils	ils	NOUN
dti-2355	50	34	and	and	CCONJ
dti-2355	50	35	chemokines	chemokine	NOUN
dti-2355	50	36	(	(	PUNCT
dti-2355	50	37	8)	8)	NUM
dti-2355	50	38	.	.	PUNCT
dti-2355	51	1	the	the	DET
dti-2355	51	2	homodimeric	homodimeric	ADJ
dti-2355	51	3	glycoprotein	glycoprotein	NOUN
dti-2355	51	4	il-17a	il-17a	PROPN
dti-2355	51	5	belongs	belong	VERB
dti-2355	51	6	to	to	ADP
dti-2355	51	7	the	the	DET
dti-2355	51	8	il-17	il-17	NUM
dti-2355	51	9	family	family	NOUN
dti-2355	51	10	and	and	CCONJ
dti-2355	51	11	through	through	ADP
dti-2355	51	12	its	its	PRON
dti-2355	51	13	receptor	receptor	NOUN
dti-2355	51	14	complex	complex	NOUN
dti-2355	51	15	il-17ra	il-17ra	PROPN
dti-2355	51	16	/	/	SYM
dti-2355	51	17	il-17rc	il-17rc	PROPN
dti-2355	51	18	binds	bind	VERB
dti-2355	51	19	to	to	ADP
dti-2355	51	20	keratinocytes	keratinocyte	NOUN
dti-2355	51	21	,	,	PUNCT
dti-2355	51	22	dendritic	dendritic	ADJ
dti-2355	51	23	cells	cell	NOUN
dti-2355	51	24	,	,	PUNCT
dti-2355	51	25	dermal	dermal	ADJ
dti-2355	51	26	fibroblast	fibroblast	NOUN
dti-2355	51	27	,	,	PUNCT
dti-2355	51	28	and	and	CCONJ
dti-2355	51	29	endothelial	endothelial	ADJ
dti-2355	51	30	cells	cell	NOUN
dti-2355	51	31	.	.	PUNCT
dti-2355	52	1	under	under	ADP
dti-2355	52	2	physiological	physiological	ADJ
dti-2355	52	3	conditions	condition	NOUN
dti-2355	52	4	,	,	PUNCT
dti-2355	52	5	normal	normal	ADJ
dti-2355	52	6	levels	level	NOUN
dti-2355	52	7	of	of	ADP
dti-2355	52	8	il-17a	il-17a	PROPN
dti-2355	52	9	promote	promote	NOUN
dti-2355	52	10	,	,	PUNCT
dti-2355	52	11	upon	upon	SCONJ
dti-2355	52	12	binding	bind	VERB
dti-2355	52	13	,	,	PUNCT
dti-2355	52	14	the	the	DET
dti-2355	52	15	proliferation	proliferation	NOUN
dti-2355	52	16	of	of	ADP
dti-2355	52	17	the	the	DET
dti-2355	52	18	keratinocytes	keratinocyte	NOUN
dti-2355	52	19	necessary	necessary	ADJ
dti-2355	52	20	for	for	ADP
dti-2355	52	21	healing	healing	NOUN
dti-2355	52	22	,	,	PUNCT
dti-2355	52	23	and	and	CCONJ
dti-2355	52	24	protect	protect	VERB
dti-2355	52	25	against	against	ADP
dti-2355	52	26	infectious	infectious	ADJ
dti-2355	52	27	agents	agent	NOUN
dti-2355	52	28	.	.	PUNCT
dti-2355	53	1	however	however	ADV
dti-2355	53	2	,	,	PUNCT
dti-2355	53	3	in	in	ADP
dti-2355	53	4	psoriatic	psoriatic	ADJ
dti-2355	53	5	patients	patient	NOUN
dti-2355	53	6	,	,	PUNCT
dti-2355	53	7	levels	level	NOUN
dti-2355	53	8	of	of	ADP
dti-2355	53	9	il-17a	il-17a	PROPN
dti-2355	53	10	are	be	AUX
dti-2355	53	11	elevated	elevate	VERB
dti-2355	53	12	,	,	PUNCT
dti-2355	53	13	and	and	CCONJ
dti-2355	53	14	correlate	correlate	VERB
dti-2355	53	15	with	with	ADP
dti-2355	53	16	the	the	DET
dti-2355	53	17	severity	severity	NOUN
dti-2355	53	18	of	of	ADP
dti-2355	53	19	the	the	DET
dti-2355	53	20	disease	disease	NOUN
dti-2355	53	21	.	.	PUNCT
dti-2355	54	1	keratinocytes	keratinocyte	VERB
dti-2355	54	2	themselves	themselves	PRON
dti-2355	54	3	,	,	PUNCT
dti-2355	54	4	when	when	SCONJ
dti-2355	54	5	stimulated	stimulate	VERB
dti-2355	54	6	,	,	PUNCT
dti-2355	54	7	also	also	ADV
dti-2355	54	8	synthesize	synthesize	VERB
dti-2355	54	9	many	many	ADJ
dti-2355	54	10	cytokines	cytokine	NOUN
dti-2355	54	11	that	that	PRON
dti-2355	54	12	can	can	AUX
dti-2355	54	13	induce	induce	VERB
dti-2355	54	14	epidermal	epidermal	ADJ
dti-2355	54	15	hyperplasia	hyperplasia	NOUN
dti-2355	54	16	(	(	PUNCT
dti-2355	54	17	autocrine	autocrine	NOUN
dti-2355	54	18	growth	growth	NOUN
dti-2355	54	19	factors	factor	NOUN
dti-2355	54	20	)	)	PUNCT
dti-2355	54	21	or	or	CCONJ
dti-2355	54	22	neoangiogenesis	neoangiogenesis	NOUN
dti-2355	54	23	(	(	PUNCT
dti-2355	54	24	paracrine	paracrine	ADJ
dti-2355	54	25	growth	growth	NOUN
dti-2355	54	26	factors	factor	NOUN
dti-2355	54	27	)	)	PUNCT
dti-2355	54	28	,	,	PUNCT
dti-2355	54	29	resulting	result	VERB
dti-2355	54	30	in	in	ADP
dti-2355	54	31	worsening	worsen	VERB
dti-2355	54	32	of	of	ADP
dti-2355	54	33	ep	ep	PROPN
dti-2355	54	34	and	and	CCONJ
dti-2355	54	35	initiating	initiate	VERB
dti-2355	54	36	a	a	DET
dti-2355	54	37	reverberating	reverberate	VERB
dti-2355	54	38	loop	loop	NOUN
dti-2355	54	39	that	that	PRON
dti-2355	54	40	perpetuates	perpetuate	VERB
dti-2355	54	41	pro	pro	ADJ
dti-2355	54	42	-	-	ADJ
dti-2355	54	43	proliferative	proliferative	ADJ
dti-2355	54	44	and	and	CCONJ
dti-2355	54	45	proinflammatory	proinflammatory	ADJ
dti-2355	54	46	stimuli	stimulus	NOUN
dti-2355	54	47	(	(	PUNCT
dti-2355	54	48	9	9	NUM
dti-2355	54	49	)	)	PUNCT
dti-2355	54	50	.	.	PUNCT
dti-2355	55	1	consistently	consistently	ADV
dti-2355	55	2	,	,	PUNCT
dti-2355	55	3	blocking	block	VERB
dti-2355	55	4	il-17a	il-17a	PROPN
dti-2355	55	5	results	result	VERB
dti-2355	55	6	in	in	ADP
dti-2355	55	7	an	an	DET
dti-2355	55	8	improvement	improvement	NOUN
dti-2355	55	9	of	of	ADP
dti-2355	55	10	psoriasis	psoriasis	NOUN
dti-2355	55	11	lesions	lesion	NOUN
dti-2355	55	12	,	,	PUNCT
dti-2355	55	13	suggesting	suggest	VERB
dti-2355	55	14	a	a	DET
dti-2355	55	15	key	key	ADJ
dti-2355	55	16	role	role	NOUN
dti-2355	55	17	in	in	ADP
dti-2355	55	18	the	the	DET
dti-2355	55	19	pathogenesis	pathogenesis	NOUN
dti-2355	55	20	of	of	ADP
dti-2355	55	21	ep	ep	PROPN
dti-2355	55	22	(	(	PUNCT
dti-2355	55	23	8)	8)	NUM
dti-2355	55	24	.	.	PUNCT
dti-2355	56	1	currently	currently	ADV
dti-2355	56	2	,	,	PUNCT
dti-2355	56	3	one	one	NUM
dti-2355	56	4	anti	anti	ADJ
dti-2355	56	5	-	-	ADJ
dti-2355	56	6	il-17a	il-17a	ADJ
dti-2355	56	7	biological	biological	ADJ
dti-2355	56	8	agent	agent	NOUN
dti-2355	56	9	is	be	AUX
dti-2355	56	10	approved	approve	VERB
dti-2355	56	11	for	for	ADP
dti-2355	56	12	the	the	DET
dti-2355	56	13	treatment	treatment	NOUN
dti-2355	56	14	of	of	ADP
dti-2355	56	15	plaque	plaque	NOUN
dti-2355	56	16	psoriasis	psoriasis	NOUN
dti-2355	56	17	,	,	PUNCT
dti-2355	56	18	secukinumab	secukinumab	NOUN
dti-2355	56	19	,	,	PUNCT
dti-2355	56	20	a	a	DET
dti-2355	56	21	monoclonal	monoclonal	NOUN
dti-2355	56	22	antibody	antibody	NOUN
dti-2355	56	23	that	that	PRON
dti-2355	56	24	targets	target	VERB
dti-2355	56	25	il-17a	il-17a	PROPN
dti-2355	56	26	(	(	PUNCT
dti-2355	56	27	10	10	NUM
dti-2355	56	28	)	)	PUNCT
dti-2355	56	29	.	.	PUNCT
dti-2355	57	1	secukinumab	secukinumab	NOUN
dti-2355	57	2	is	be	AUX
dti-2355	57	3	a	a	DET
dti-2355	57	4	novel	novel	ADJ
dti-2355	57	5	biologic	biologic	NOUN
dti-2355	57	6	agent	agent	NOUN
dti-2355	57	7	that	that	PRON
dti-2355	57	8	specifically	specifically	ADV
dti-2355	57	9	targets	target	VERB
dti-2355	57	10	il-17a	il-17a	PROPN
dti-2355	57	11	.	.	PUNCT
dti-2355	58	1	it	it	PRON
dti-2355	58	2	is	be	AUX
dti-2355	58	3	a	a	DET
dti-2355	58	4	fully	fully	ADV
dti-2355	58	5	human	human	ADJ
dti-2355	58	6	monoclonal	monoclonal	NOUN
dti-2355	58	7	antibody	antibody	NOUN
dti-2355	58	8	,	,	PUNCT
dti-2355	58	9	and	and	CCONJ
dti-2355	58	10	many	many	ADJ
dti-2355	58	11	clinical	clinical	ADJ
dti-2355	58	12	trials	trial	NOUN
dti-2355	58	13	have	have	AUX
dti-2355	58	14	demonstrated	demonstrate	VERB
dti-2355	58	15	its	its	PRON
dti-2355	58	16	efficacy	efficacy	NOUN
dti-2355	58	17	in	in	ADP
dti-2355	58	18	the	the	DET
dti-2355	58	19	treatment	treatment	NOUN
dti-2355	58	20	of	of	ADP
dti-2355	58	21	plaque	plaque	NOUN
dti-2355	58	22	psoriasis	psoriasis	NOUN
dti-2355	58	23	,	,	PUNCT
dti-2355	58	24	psoriatic	psoriatic	ADJ
dti-2355	58	25	arthritis	arthritis	NOUN
dti-2355	58	26	,	,	PUNCT
dti-2355	58	27	and	and	CCONJ
dti-2355	58	28	ankylosing	ankylose	VERB
dti-2355	58	29	spondylitis	spondylitis	NOUN
dti-2355	58	30	(	(	PUNCT
dti-2355	58	31	as	as	ADP
dti-2355	58	32	)	)	PUNCT
dti-2355	58	33	(	(	PUNCT
dti-2355	58	34	11	11	NUM
dti-2355	58	35	-	-	SYM
dti-2355	58	36	14	14	NUM
dti-2355	58	37	)	)	PUNCT
dti-2355	58	38	.	.	PUNCT
dti-2355	59	1	indications	indication	NOUN
dti-2355	59	2	approved	approve	VERB
dti-2355	59	3	by	by	ADP
dti-2355	59	4	the	the	DET
dti-2355	59	5	european	european	PROPN
dti-2355	59	6	medicines	medicines	PROPN
dti-2355	59	7	agency	agency	NOUN
dti-2355	59	8	(	(	PUNCT
dti-2355	59	9	ema	ema	PROPN
dti-2355	59	10	)	)	PUNCT
dti-2355	59	11	include	include	VERB
dti-2355	59	12	adult	adult	NOUN
dti-2355	59	13	and	and	CCONJ
dti-2355	59	14	pediatric	pediatric	ADJ
dti-2355	59	15	psoriasis	psoriasis	NOUN
dti-2355	59	16	,	,	PUNCT
dti-2355	59	17	psoriatic	psoriatic	ADJ
dti-2355	59	18	arthritis	arthritis	NOUN
dti-2355	59	19	,	,	PUNCT
dti-2355	59	20	axial	axial	ADJ
dti-2355	59	21	spondyloarthritis	spondyloarthritis	NOUN
dti-2355	59	22	(	(	PUNCT
dti-2355	59	23	axspa	axspa	NOUN
dti-2355	59	24	)	)	PUNCT
dti-2355	59	25	,	,	PUNCT
dti-2355	59	26	as	as	ADP
dti-2355	59	27	and	and	CCONJ
dti-2355	59	28	non	non	ADJ
dti-2355	59	29	-	-	ADJ
dti-2355	59	30	radiographic	radiographic	ADJ
dti-2355	59	31	axial	axial	ADJ
dti-2355	59	32	spondyloarthritis	spondyloarthritis	NOUN
dti-2355	59	33	(	(	PUNCT
dti-2355	59	34	nr	nr	NOUN
dti-2355	59	35	-	-	NOUN
dti-2355	59	36	axspa	axspa	NOUN
dti-2355	59	37	)	)	PUNCT
dti-2355	59	38	(	(	PUNCT
dti-2355	59	39	15	15	NUM
dti-2355	59	40	)	)	PUNCT
dti-2355	59	41	.	.	PUNCT
dti-2355	60	1	the	the	DET
dti-2355	60	2	rationale	rationale	NOUN
dti-2355	60	3	behind	behind	ADP
dti-2355	60	4	the	the	DET
dti-2355	60	5	efficacy	efficacy	NOUN
dti-2355	60	6	and	and	CCONJ
dti-2355	60	7	mechanism	mechanism	NOUN
dti-2355	60	8	of	of	ADP
dti-2355	60	9	the	the	DET
dti-2355	60	10	action	action	NOUN
dti-2355	60	11	of	of	ADP
dti-2355	60	12	secukinumab	secukinumab	NOUN
dti-2355	60	13	is	be	AUX
dti-2355	60	14	a	a	DET
dti-2355	60	15	targeted	targeted	ADJ
dti-2355	60	16	approach	approach	NOUN
dti-2355	60	17	to	to	PART
dti-2355	60	18	block	block	VERB
dti-2355	60	19	the	the	DET
dti-2355	60	20	disease	disease	NOUN
dti-2355	60	21	process	process	NOUN
dti-2355	60	22	at	at	ADP
dti-2355	60	23	a	a	DET
dti-2355	60	24	very	very	ADV
dti-2355	60	25	early	early	ADJ
dti-2355	60	26	stage	stage	NOUN
dti-2355	60	27	along	along	ADP
dti-2355	60	28	with	with	ADP
dti-2355	60	29	a	a	DET
dti-2355	60	30	safe	safe	ADJ
dti-2355	60	31	adverse	adverse	ADJ
dti-2355	60	32	event	event	NOUN
dti-2355	60	33	profile	profile	NOUN
dti-2355	60	34	(	(	PUNCT
dti-2355	60	35	16	16	NUM
dti-2355	60	36	)	)	PUNCT
dti-2355	60	37	.	.	PUNCT
dti-2355	61	1	by	by	ADP
dti-2355	61	2	targeting	target	VERB
dti-2355	61	3	il-17a	il-17a	PROPN
dti-2355	61	4	,	,	PUNCT
dti-2355	61	5	secukinumab	secukinumab	NOUN
dti-2355	61	6	thereby	thereby	ADV
dti-2355	61	7	blocks	block	VERB
dti-2355	61	8	its	its	PRON
dti-2355	61	9	binding	binding	NOUN
dti-2355	61	10	with	with	ADP
dti-2355	61	11	il-17r	il-17r	NOUN
dti-2355	61	12	and	and	CCONJ
dti-2355	61	13	consequent	consequent	ADJ
dti-2355	61	14	expression	expression	NOUN
dti-2355	61	15	of	of	ADP
dti-2355	61	16	cytokines	cytokine	NOUN
dti-2355	61	17	.	.	PUNCT
dti-2355	62	1	blocking	block	VERB
dti-2355	62	2	the	the	DET
dti-2355	62	3	il-17a	il-17a	PROPN
dti-2355	62	4	pathway	pathway	NOUN
dti-2355	62	5	leads	lead	VERB
dti-2355	62	6	to	to	ADP
dti-2355	62	7	a	a	DET
dti-2355	62	8	normalization	normalization	NOUN
dti-2355	62	9	of	of	ADP
dti-2355	62	10	the	the	DET
dti-2355	62	11	inflammatory	inflammatory	ADJ
dti-2355	62	12	processes	process	NOUN
dti-2355	62	13	and	and	CCONJ
dti-2355	62	14	thus	thus	ADV
dti-2355	62	15	combats	combat	VERB
dti-2355	62	16	epidermal	epidermal	ADJ
dti-2355	62	17	carriero	carriero	NOUN
dti-2355	62	18	drug	drug	NOUN
dti-2355	62	19	target	target	NOUN
dti-2355	62	20	insights	insight	NOUN
dti-2355	62	21	2022	2022	NUM
dti-2355	62	22	;	;	PUNCT
dti-2355	62	23	16	16	NUM
dti-2355	62	24	:	:	SYM
dti-2355	62	25	3	3	NUM
dti-2355	62	26	©	©	PROPN
dti-2355	62	27	2022	2022	NUM
dti-2355	62	28	the	the	DET
dti-2355	62	29	authors	author	NOUN
dti-2355	62	30	.	.	PUNCT
dti-2355	63	1	published	publish	VERB
dti-2355	63	2	by	by	ADP
dti-2355	63	3	aboutscience	aboutscience	NOUN
dti-2355	63	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2355	63	5	hyperproliferation	hyperproliferation	PROPN
dti-2355	63	6	,	,	PUNCT
dti-2355	63	7	t	t	NOUN
dti-2355	63	8	-	-	PUNCT
dti-2355	63	9	cell	cell	NOUN
dti-2355	63	10	infiltration	infiltration	NOUN
dti-2355	63	11	,	,	PUNCT
dti-2355	63	12	and	and	CCONJ
dti-2355	63	13	excessive	excessive	ADJ
dti-2355	63	14	expression	expression	NOUN
dti-2355	63	15	of	of	ADP
dti-2355	63	16	pathogenic	pathogenic	ADJ
dti-2355	63	17	genes	gene	NOUN
dti-2355	63	18	(	(	PUNCT
dti-2355	63	19	16	16	NUM
dti-2355	63	20	)	)	PUNCT
dti-2355	63	21	.	.	PUNCT
dti-2355	64	1	several	several	ADJ
dti-2355	64	2	clinical	clinical	ADJ
dti-2355	64	3	trials	trial	NOUN
dti-2355	64	4	have	have	AUX
dti-2355	64	5	demonstrated	demonstrate	VERB
dti-2355	64	6	the	the	DET
dti-2355	64	7	efficacy	efficacy	NOUN
dti-2355	64	8	of	of	ADP
dti-2355	64	9	secukinumab	secukinumab	NOUN
dti-2355	64	10	in	in	ADP
dti-2355	64	11	the	the	DET
dti-2355	64	12	treatment	treatment	NOUN
dti-2355	64	13	of	of	ADP
dti-2355	64	14	psoriasis	psoriasis	NOUN
dti-2355	64	15	(	(	PUNCT
dti-2355	64	16	11	11	NUM
dti-2355	64	17	-	-	SYM
dti-2355	64	18	14	14	NUM
dti-2355	64	19	)	)	PUNCT
dti-2355	64	20	.	.	PUNCT
dti-2355	65	1	two	two	NUM
dti-2355	65	2	phase	phase	NOUN
dti-2355	65	3	iii	iii	NOUN
dti-2355	65	4	,	,	PUNCT
dti-2355	65	5	double	double	ADJ
dti-2355	65	6	-	-	PUNCT
dti-2355	65	7	blind	blind	ADJ
dti-2355	65	8	,	,	PUNCT
dti-2355	65	9	52	52	NUM
dti-2355	65	10	-	-	PUNCT
dti-2355	65	11	week	week	NOUN
dti-2355	65	12	trials	trial	NOUN
dti-2355	65	13	(	(	PUNCT
dti-2355	65	14	erasure	erasure	NOUN
dti-2355	65	15	and	and	CCONJ
dti-2355	65	16	fixture	fixture	NOUN
dti-2355	65	17	)	)	PUNCT
dti-2355	65	18	(	(	PUNCT
dti-2355	65	19	17	17	NUM
dti-2355	65	20	)	)	PUNCT
dti-2355	65	21	evaluated	evaluate	VERB
dti-2355	65	22	the	the	DET
dti-2355	65	23	efficacy	efficacy	NOUN
dti-2355	65	24	of	of	ADP
dti-2355	65	25	secukinumab	secukinumab	NOUN
dti-2355	65	26	in	in	ADP
dti-2355	65	27	patients	patient	NOUN
dti-2355	65	28	with	with	ADP
dti-2355	65	29	moderate	moderate	ADJ
dti-2355	65	30	-	-	PUNCT
dti-2355	65	31	to	to	ADP
dti-2355	65	32	-	-	PUNCT
dti-2355	65	33	severe	severe	ADJ
dti-2355	65	34	plaque	plaque	NOUN
dti-2355	65	35	psoriasis	psoriasis	NOUN
dti-2355	65	36	.	.	PUNCT
dti-2355	66	1	the	the	DET
dti-2355	66	2	erasure	erasure	NOUN
dti-2355	66	3	study	study	NOUN
dti-2355	66	4	enrolled	enrol	VERB
dti-2355	66	5	738	738	NUM
dti-2355	66	6	patients	patient	NOUN
dti-2355	66	7	,	,	PUNCT
dti-2355	66	8	while	while	SCONJ
dti-2355	66	9	fixture	fixture	ADJ
dti-2355	66	10	study	study	NOUN
dti-2355	66	11	included	include	VERB
dti-2355	66	12	1,306	1,306	NUM
dti-2355	66	13	patients	patient	NOUN
dti-2355	66	14	.	.	PUNCT
dti-2355	67	1	in	in	ADP
dti-2355	67	2	both	both	DET
dti-2355	67	3	studies	study	NOUN
dti-2355	67	4	patients	patient	NOUN
dti-2355	67	5	received	receive	VERB
dti-2355	67	6	either	either	PRON
dti-2355	67	7	placebo	placebo	NOUN
dti-2355	67	8	or	or	CCONJ
dti-2355	67	9	secukinumab	secukinumab	NOUN
dti-2355	67	10	subcutaneously	subcutaneously	ADV
dti-2355	67	11	once	once	ADV
dti-2355	67	12	a	a	DET
dti-2355	67	13	week	week	NOUN
dti-2355	67	14	for	for	ADP
dti-2355	67	15	5	5	NUM
dti-2355	67	16	weeks	week	NOUN
dti-2355	67	17	,	,	PUNCT
dti-2355	67	18	but	but	CCONJ
dti-2355	67	19	in	in	ADP
dti-2355	67	20	the	the	DET
dti-2355	67	21	fixture	fixture	NOUN
dti-2355	67	22	study	study	NOUN
dti-2355	67	23	patients	patient	NOUN
dti-2355	67	24	also	also	ADV
dti-2355	67	25	received	receive	VERB
dti-2355	67	26	etanercept	etanercept	NOUN
dti-2355	67	27	(	(	PUNCT
dti-2355	67	28	50	50	NUM
dti-2355	67	29	mg	mg	NOUN
dti-2355	67	30	twice	twice	DET
dti-2355	67	31	a	a	DET
dti-2355	67	32	week	week	NOUN
dti-2355	67	33	for	for	ADP
dti-2355	67	34	12	12	NUM
dti-2355	67	35	weeks	week	NOUN
dti-2355	67	36	,	,	PUNCT
dti-2355	67	37	then	then	ADV
dti-2355	67	38	once	once	ADV
dti-2355	67	39	a	a	DET
dti-2355	67	40	week	week	NOUN
dti-2355	67	41	)	)	PUNCT
dti-2355	67	42	.	.	PUNCT
dti-2355	68	1	results	result	NOUN
dti-2355	68	2	from	from	ADP
dti-2355	68	3	the	the	DET
dti-2355	68	4	erasure	erasure	NOUN
dti-2355	68	5	study	study	NOUN
dti-2355	68	6	showed	show	VERB
dti-2355	68	7	that	that	SCONJ
dti-2355	68	8	a	a	DET
dti-2355	68	9	psoriasis	psoriasis	NOUN
dti-2355	68	10	area	area	NOUN
dti-2355	68	11	and	and	CCONJ
dti-2355	68	12	severity	severity	NOUN
dti-2355	68	13	index	index	NOUN
dti-2355	68	14	(	(	PUNCT
dti-2355	68	15	pasi	pasi	NOUN
dti-2355	68	16	)	)	PUNCT
dti-2355	68	17	75	75	NUM
dti-2355	68	18	score	score	NOUN
dti-2355	68	19	at	at	ADP
dti-2355	68	20	week	week	NOUN
dti-2355	68	21	12	12	NUM
dti-2355	68	22	was	be	AUX
dti-2355	68	23	achieved	achieve	VERB
dti-2355	68	24	by	by	ADP
dti-2355	68	25	81.6	81.6	NUM
dti-2355	68	26	%	%	NOUN
dti-2355	68	27	and	and	CCONJ
dti-2355	68	28	71.6	71.6	NUM
dti-2355	68	29	%	%	NOUN
dti-2355	68	30	of	of	ADP
dti-2355	68	31	patients	patient	NOUN
dti-2355	68	32	administered	administer	VERB
dti-2355	68	33	with	with	ADP
dti-2355	68	34	300	300	NUM
dti-2355	68	35	mg	mg	NOUN
dti-2355	68	36	and	and	CCONJ
dti-2355	68	37	150	150	NUM
dti-2355	68	38	mg	mg	NOUN
dti-2355	68	39	of	of	ADP
dti-2355	68	40	secukinumab	secukinumab	NOUN
dti-2355	68	41	,	,	PUNCT
dti-2355	68	42	respectively	respectively	ADV
dti-2355	68	43	,	,	PUNCT
dti-2355	68	44	and	and	CCONJ
dti-2355	68	45	by	by	ADP
dti-2355	68	46	4.5	4.5	NUM
dti-2355	68	47	%	%	NOUN
dti-2355	68	48	of	of	ADP
dti-2355	68	49	placebo	placebo	NOUN
dti-2355	68	50	recipients	recipient	NOUN
dti-2355	68	51	.	.	PUNCT
dti-2355	69	1	corresponding	correspond	VERB
dti-2355	69	2	results	result	NOUN
dti-2355	69	3	from	from	ADP
dti-2355	69	4	fixture	fixture	NOUN
dti-2355	69	5	showed	show	VERB
dti-2355	69	6	that	that	SCONJ
dti-2355	69	7	77.1	77.1	NUM
dti-2355	69	8	%	%	NOUN
dti-2355	69	9	of	of	ADP
dti-2355	69	10	patients	patient	NOUN
dti-2355	69	11	administered	administer	VERB
dti-2355	69	12	300	300	NUM
dti-2355	69	13	mg	mg	NOUN
dti-2355	69	14	of	of	ADP
dti-2355	69	15	secukinumab	secukinumab	NOUN
dti-2355	69	16	,	,	PUNCT
dti-2355	69	17	67	67	NUM
dti-2355	69	18	%	%	NOUN
dti-2355	69	19	of	of	ADP
dti-2355	69	20	those	those	PRON
dti-2355	69	21	administered	administer	VERB
dti-2355	69	22	150	150	NUM
dti-2355	69	23	mg	mg	NOUN
dti-2355	69	24	of	of	ADP
dti-2355	69	25	secukinumab	secukinumab	NOUN
dti-2355	69	26	,	,	PUNCT
dti-2355	69	27	44	44	NUM
dti-2355	69	28	%	%	NOUN
dti-2355	69	29	of	of	ADP
dti-2355	69	30	etanercept	etanercept	NOUN
dti-2355	69	31	recipients	recipient	NOUN
dti-2355	69	32	,	,	PUNCT
dti-2355	69	33	and	and	CCONJ
dti-2355	69	34	only	only	ADV
dti-2355	69	35	4.9	4.9	NUM
dti-2355	69	36	%	%	NOUN
dti-2355	69	37	of	of	ADP
dti-2355	69	38	placebo	placebo	NOUN
dti-2355	69	39	patients	patient	NOUN
dti-2355	69	40	achieved	achieve	VERB
dti-2355	69	41	pasi	pasi	NOUN
dti-2355	69	42	75	75	NUM
dti-2355	69	43	score	score	NOUN
dti-2355	69	44	at	at	ADP
dti-2355	69	45	week	week	NOUN
dti-2355	69	46	12	12	NUM
dti-2355	69	47	(	(	PUNCT
dti-2355	69	48	17	17	NUM
dti-2355	69	49	)	)	PUNCT
dti-2355	69	50	.	.	PUNCT
dti-2355	70	1	another	another	DET
dti-2355	70	2	multicenter	multicenter	NOUN
dti-2355	70	3	,	,	PUNCT
dti-2355	70	4	international	international	ADJ
dti-2355	70	5	,	,	PUNCT
dti-2355	70	6	retrospective	retrospective	ADJ
dti-2355	70	7	,	,	PUNCT
dti-2355	70	8	pilot	pilot	NOUN
dti-2355	70	9	study	study	NOUN
dti-2355	70	10	enrolled	enrol	VERB
dti-2355	70	11	13	13	NUM
dti-2355	70	12	ep	ep	PROPN
dti-2355	70	13	patients	patient	NOUN
dti-2355	70	14	who	who	PRON
dti-2355	70	15	were	be	AUX
dti-2355	70	16	treated	treat	VERB
dti-2355	70	17	with	with	ADP
dti-2355	70	18	a	a	DET
dti-2355	70	19	loading	loading	NOUN
dti-2355	70	20	dose	dose	NOUN
dti-2355	70	21	of	of	ADP
dti-2355	70	22	300	300	NUM
dti-2355	70	23	mg	mg	NOUN
dti-2355	70	24	of	of	ADP
dti-2355	70	25	subcutaneous	subcutaneous	ADJ
dti-2355	70	26	secukinumab	secukinumab	NOUN
dti-2355	70	27	at	at	ADP
dti-2355	70	28	weeks	week	NOUN
dti-2355	70	29	0	0	NUM
dti-2355	70	30	,	,	PUNCT
dti-2355	70	31	1	1	NUM
dti-2355	70	32	,	,	PUNCT
dti-2355	70	33	2	2	NUM
dti-2355	70	34	,	,	PUNCT
dti-2355	70	35	3	3	NUM
dti-2355	70	36	,	,	PUNCT
dti-2355	70	37	and	and	CCONJ
dti-2355	70	38	4	4	NUM
dti-2355	70	39	,	,	PUNCT
dti-2355	70	40	followed	follow	VERB
dti-2355	70	41	by	by	ADP
dti-2355	70	42	300	300	NUM
dti-2355	70	43	mg	mg	NOUN
dti-2355	70	44	every	every	DET
dti-2355	70	45	4	4	NUM
dti-2355	70	46	weeks	week	NOUN
dti-2355	70	47	(	(	PUNCT
dti-2355	70	48	18	18	NUM
dti-2355	70	49	)	)	PUNCT
dti-2355	70	50	.	.	PUNCT
dti-2355	71	1	results	result	NOUN
dti-2355	71	2	from	from	ADP
dti-2355	71	3	this	this	DET
dti-2355	71	4	study	study	NOUN
dti-2355	71	5	showed	show	VERB
dti-2355	71	6	that	that	SCONJ
dti-2355	71	7	the	the	DET
dti-2355	71	8	response	response	NOUN
dti-2355	71	9	rate	rate	NOUN
dti-2355	71	10	to	to	PART
dti-2355	71	11	secukinumab	secukinumab	NOUN
dti-2355	71	12	was	be	AUX
dti-2355	71	13	10/13	10/13	NUM
dti-2355	71	14	patients	patient	NOUN
dti-2355	71	15	(	(	PUNCT
dti-2355	71	16	77	77	NUM
dti-2355	71	17	%	%	NOUN
dti-2355	71	18	)	)	PUNCT
dti-2355	71	19	,	,	PUNCT
dti-2355	71	20	with	with	ADP
dti-2355	71	21	a	a	DET
dti-2355	71	22	median	median	ADJ
dti-2355	71	23	time	time	NOUN
dti-2355	71	24	to	to	ADP
dti-2355	71	25	clearance	clearance	NOUN
dti-2355	71	26	of	of	ADP
dti-2355	71	27	3	3	NUM
dti-2355	71	28	weeks	week	NOUN
dti-2355	71	29	(	(	PUNCT
dti-2355	71	30	1.5	1.5	NUM
dti-2355	71	31	-	-	SYM
dti-2355	71	32	3	3	NUM
dti-2355	71	33	weeks	week	NOUN
dti-2355	71	34	)	)	PUNCT
dti-2355	71	35	.	.	PUNCT
dti-2355	72	1	no	no	DET
dti-2355	72	2	recurrences	recurrence	NOUN
dti-2355	72	3	were	be	AUX
dti-2355	72	4	registered	register	VERB
dti-2355	72	5	in	in	ADP
dti-2355	72	6	the	the	DET
dti-2355	72	7	52	52	NUM
dti-2355	72	8	-	-	PUNCT
dti-2355	72	9	week	week	NOUN
dti-2355	72	10	follow	follow	NOUN
dti-2355	72	11	-	-	PUNCT
dti-2355	72	12	up	up	NOUN
dti-2355	72	13	and	and	CCONJ
dti-2355	72	14	a	a	DET
dti-2355	72	15	pasi	pasi	NOUN
dti-2355	72	16	score	score	NOUN
dti-2355	72	17	of	of	ADP
dti-2355	72	18	90	90	NUM
dti-2355	72	19	was	be	AUX
dti-2355	72	20	achieved	achieve	VERB
dti-2355	72	21	by	by	ADP
dti-2355	72	22	10/13	10/13	NUM
dti-2355	72	23	patients	patient	NOUN
dti-2355	72	24	.	.	PUNCT
dti-2355	73	1	these	these	DET
dti-2355	73	2	results	result	NOUN
dti-2355	73	3	demonstrated	demonstrate	VERB
dti-2355	73	4	that	that	SCONJ
dti-2355	73	5	secukinumab	secukinumab	NOUN
dti-2355	73	6	remains	remain	VERB
dti-2355	73	7	a	a	DET
dti-2355	73	8	valid	valid	ADJ
dti-2355	73	9	and	and	CCONJ
dti-2355	73	10	effective	effective	ADJ
dti-2355	73	11	therapeutic	therapeutic	ADJ
dti-2355	73	12	option	option	NOUN
dti-2355	73	13	for	for	ADP
dti-2355	73	14	ep	ep	PROPN
dti-2355	73	15	(	(	PUNCT
dti-2355	73	16	18	18	NUM
dti-2355	73	17	)	)	PUNCT
dti-2355	73	18	.	.	PUNCT
dti-2355	74	1	case	case	NOUN
dti-2355	74	2	presentation	presentation	NOUN
dti-2355	74	3	in	in	ADP
dti-2355	74	4	this	this	DET
dti-2355	74	5	real	real	ADJ
dti-2355	74	6	-	-	PUNCT
dti-2355	74	7	life	life	NOUN
dti-2355	74	8	clinical	clinical	ADJ
dti-2355	74	9	experience	experience	NOUN
dti-2355	74	10	of	of	ADP
dti-2355	74	11	the	the	DET
dti-2355	74	12	treatment	treatment	NOUN
dti-2355	74	13	of	of	ADP
dti-2355	74	14	psoriasis	psoriasis	NOUN
dti-2355	74	15	with	with	ADP
dti-2355	74	16	secukinumab	secukinumab	NOUN
dti-2355	74	17	drug	drug	NOUN
dti-2355	74	18	,	,	PUNCT
dti-2355	74	19	we	we	PRON
dti-2355	74	20	report	report	VERB
dti-2355	74	21	the	the	DET
dti-2355	74	22	case	case	NOUN
dti-2355	74	23	of	of	ADP
dti-2355	74	24	a	a	DET
dti-2355	74	25	72	72	NUM
dti-2355	74	26	-	-	PUNCT
dti-2355	74	27	year	year	NOUN
dti-2355	74	28	-	-	PUNCT
dti-2355	74	29	old	old	ADJ
dti-2355	74	30	man	man	NOUN
dti-2355	74	31	,	,	PUNCT
dti-2355	74	32	in	in	ADP
dti-2355	74	33	general	general	ADJ
dti-2355	74	34	good	good	ADJ
dti-2355	74	35	health	health	NOUN
dti-2355	74	36	condition	condition	NOUN
dti-2355	74	37	,	,	PUNCT
dti-2355	74	38	who	who	PRON
dti-2355	74	39	contacted	contact	VERB
dti-2355	74	40	the	the	DET
dti-2355	74	41	dermatologic	dermatologic	ADJ
dti-2355	74	42	outpatient	outpatient	NOUN
dti-2355	74	43	clinic	clinic	NOUN
dti-2355	74	44	of	of	ADP
dti-2355	74	45	the	the	DET
dti-2355	74	46	author	author	NOUN
dti-2355	74	47	on	on	ADP
dti-2355	74	48	march	march	PROPN
dti-2355	74	49	5	5	NUM
dti-2355	74	50	,	,	PUNCT
dti-2355	74	51	2020	2020	NUM
dti-2355	74	52	,	,	PUNCT
dti-2355	74	53	during	during	ADP
dti-2355	74	54	the	the	DET
dti-2355	74	55	pandemic	pandemic	ADJ
dti-2355	74	56	lockdown	lockdown	NOUN
dti-2355	74	57	.	.	PUNCT
dti-2355	75	1	the	the	DET
dti-2355	75	2	patient	patient	NOUN
dti-2355	75	3	reported	report	VERB
dti-2355	75	4	widespread	widespread	ADJ
dti-2355	75	5	ep	ep	PROPN
dti-2355	75	6	with	with	ADP
dti-2355	75	7	severe	severe	ADJ
dti-2355	75	8	palmoplantar	palmoplantar	NOUN
dti-2355	75	9	hyperkeratosis	hyperkeratosis	NOUN
dti-2355	75	10	(	(	PUNCT
dti-2355	75	11	shown	show	VERB
dti-2355	75	12	in	in	ADP
dti-2355	75	13	fig	fig	NOUN
dti-2355	75	14	.	.	PUNCT
dti-2355	76	1	1a	1a	X
dti-2355	76	2	-	-	PUNCT
dti-2355	76	3	c	c	NOUN
dti-2355	76	4	)	)	PUNCT
dti-2355	76	5	,	,	PUNCT
dti-2355	76	6	and	and	CCONJ
dti-2355	76	7	he	he	PRON
dti-2355	76	8	was	be	AUX
dti-2355	76	9	not	not	PART
dti-2355	76	10	taking	take	VERB
dti-2355	76	11	any	any	DET
dti-2355	76	12	other	other	ADJ
dti-2355	76	13	drugs	drug	NOUN
dti-2355	76	14	or	or	CCONJ
dti-2355	76	15	medications	medication	NOUN
dti-2355	76	16	.	.	PUNCT
dti-2355	77	1	he	he	PRON
dti-2355	77	2	was	be	AUX
dti-2355	77	3	started	start	VERB
dti-2355	77	4	on	on	ADP
dti-2355	77	5	prednisone	prednisone	PROPN
dti-2355	77	6	(	(	PUNCT
dti-2355	77	7	25	25	NUM
dti-2355	77	8	mg	mg	PROPN
dti-2355	77	9	one	one	NUM
dti-2355	77	10	tablet	tablet	NOUN
dti-2355	77	11	)	)	PUNCT
dti-2355	77	12	treatment	treatment	NOUN
dti-2355	77	13	for	for	ADP
dti-2355	77	14	8	8	NUM
dti-2355	77	15	days	day	NOUN
dti-2355	77	16	and	and	CCONJ
dti-2355	77	17	at	at	ADP
dti-2355	77	18	half	half	ADV
dti-2355	77	19	-	-	PUNCT
dti-2355	77	20	dose	dose	NOUN
dti-2355	77	21	for	for	ADP
dti-2355	77	22	8	8	NUM
dti-2355	77	23	more	more	ADJ
dti-2355	77	24	days	day	NOUN
dti-2355	77	25	.	.	PUNCT
dti-2355	78	1	in	in	ADP
dti-2355	78	2	addition	addition	NOUN
dti-2355	78	3	,	,	PUNCT
dti-2355	78	4	topical	topical	ADJ
dti-2355	78	5	therapy	therapy	NOUN
dti-2355	78	6	with	with	ADP
dti-2355	78	7	mometasone	mometasone	NOUN
dti-2355	78	8	furoate	furoate	NOUN
dti-2355	78	9	cream	cream	NOUN
dti-2355	78	10	was	be	AUX
dti-2355	78	11	prescribed	prescribe	VERB
dti-2355	78	12	.	.	PUNCT
dti-2355	79	1	on	on	ADP
dti-2355	79	2	march	march	PROPN
dti-2355	79	3	16	16	NUM
dti-2355	79	4	,	,	PUNCT
dti-2355	79	5	2020	2020	NUM
dti-2355	79	6	,	,	PUNCT
dti-2355	79	7	blood	blood	NOUN
dti-2355	79	8	chemical	chemical	NOUN
dti-2355	79	9	tests	test	NOUN
dti-2355	79	10	were	be	AUX
dti-2355	79	11	in	in	ADP
dti-2355	79	12	the	the	DET
dti-2355	79	13	normal	normal	ADJ
dti-2355	79	14	range	range	NOUN
dti-2355	79	15	,	,	PUNCT
dti-2355	79	16	and	and	CCONJ
dti-2355	79	17	the	the	DET
dti-2355	79	18	patient	patient	NOUN
dti-2355	79	19	continued	continue	VERB
dti-2355	79	20	therapy	therapy	NOUN
dti-2355	79	21	with	with	ADP
dti-2355	79	22	cyclosporine	cyclosporine	PROPN
dti-2355	79	23	(	(	PUNCT
dti-2355	79	24	100	100	NUM
dti-2355	79	25	mg	mg	ADV
dti-2355	79	26	twice	twice	DET
dti-2355	79	27	a	a	DET
dti-2355	79	28	day	day	NOUN
dti-2355	79	29	)	)	PUNCT
dti-2355	79	30	until	until	ADP
dti-2355	79	31	july	july	PROPN
dti-2355	79	32	2020	2020	NUM
dti-2355	79	33	.	.	PUNCT
dti-2355	80	1	the	the	DET
dti-2355	80	2	patient	patient	NOUN
dti-2355	80	3	’s	’s	PART
dti-2355	80	4	erythroderma	erythroderma	NOUN
dti-2355	80	5	significantly	significantly	ADV
dti-2355	80	6	improved	improve	VERB
dti-2355	80	7	,	,	PUNCT
dti-2355	80	8	but	but	CCONJ
dti-2355	80	9	his	his	PRON
dti-2355	80	10	palmoplantar	palmoplantar	NOUN
dti-2355	80	11	hyperkeratosis	hyperkeratosis	NOUN
dti-2355	80	12	persisted	persist	VERB
dti-2355	80	13	.	.	PUNCT
dti-2355	81	1	due	due	ADP
dti-2355	81	2	to	to	ADP
dti-2355	81	3	onset	onset	NOUN
dti-2355	81	4	of	of	ADP
dti-2355	81	5	hypertensive	hypertensive	ADJ
dti-2355	81	6	seizures	seizure	NOUN
dti-2355	81	7	and	and	CCONJ
dti-2355	81	8	increased	increase	VERB
dti-2355	81	9	creatininemia	creatininemia	NOUN
dti-2355	81	10	,	,	PUNCT
dti-2355	81	11	the	the	DET
dti-2355	81	12	patient	patient	NOUN
dti-2355	81	13	discontinued	discontinue	VERB
dti-2355	81	14	the	the	DET
dti-2355	81	15	treatment	treatment	NOUN
dti-2355	81	16	.	.	PUNCT
dti-2355	82	1	then	then	ADV
dti-2355	82	2	,	,	PUNCT
dti-2355	82	3	after	after	ADP
dti-2355	82	4	a	a	DET
dti-2355	82	5	pause	pause	NOUN
dti-2355	82	6	of	of	ADP
dti-2355	82	7	a	a	DET
dti-2355	82	8	few	few	ADJ
dti-2355	82	9	weeks	week	NOUN
dti-2355	82	10	,	,	PUNCT
dti-2355	82	11	the	the	DET
dti-2355	82	12	patient	patient	NOUN
dti-2355	82	13	resumed	resume	VERB
dti-2355	82	14	prednisone	prednisone	NOUN
dti-2355	82	15	treatment	treatment	NOUN
dti-2355	82	16	in	in	ADP
dti-2355	82	17	august	august	PROPN
dti-2355	82	18	2020	2020	NUM
dti-2355	82	19	,	,	PUNCT
dti-2355	82	20	due	due	ADP
dti-2355	82	21	to	to	ADP
dti-2355	82	22	the	the	DET
dti-2355	82	23	persistence	persistence	NOUN
dti-2355	82	24	of	of	ADP
dti-2355	82	25	severe	severe	ADJ
dti-2355	82	26	hyperkeratosis	hyperkeratosis	NOUN
dti-2355	82	27	.	.	PUNCT
dti-2355	83	1	however	however	ADV
dti-2355	83	2	,	,	PUNCT
dti-2355	83	3	there	there	PRON
dti-2355	83	4	was	be	VERB
dti-2355	83	5	no	no	DET
dti-2355	83	6	response	response	NOUN
dti-2355	83	7	or	or	CCONJ
dti-2355	83	8	improvement	improvement	NOUN
dti-2355	83	9	.	.	PUNCT
dti-2355	84	1	on	on	ADP
dti-2355	84	2	september	september	PROPN
dti-2355	84	3	1	1	NUM
dti-2355	84	4	,	,	PUNCT
dti-2355	84	5	2020	2020	NUM
dti-2355	84	6	,	,	PUNCT
dti-2355	84	7	the	the	DET
dti-2355	84	8	patient	patient	NOUN
dti-2355	84	9	started	start	VERB
dti-2355	84	10	secukinumab	secukinumab	NOUN
dti-2355	84	11	treatment	treatment	NOUN
dti-2355	84	12	at	at	ADP
dti-2355	84	13	the	the	DET
dti-2355	84	14	dose	dose	NOUN
dti-2355	84	15	of	of	ADP
dti-2355	84	16	300	300	NUM
dti-2355	84	17	mg	mg	NOUN
dti-2355	84	18	administered	administer	VERB
dti-2355	84	19	by	by	ADP
dti-2355	84	20	two	two	NUM
dti-2355	84	21	subcutaneous	subcutaneous	ADJ
dti-2355	84	22	injections	injection	NOUN
dti-2355	84	23	of	of	ADP
dti-2355	84	24	150	150	NUM
dti-2355	84	25	mg	mg	NOUN
dti-2355	84	26	each	each	PRON
dti-2355	84	27	(	(	PUNCT
dti-2355	84	28	15	15	NUM
dti-2355	84	29	)	)	PUNCT
dti-2355	84	30	;	;	PUNCT
dti-2355	84	31	significant	significant	ADJ
dti-2355	84	32	signs	sign	NOUN
dti-2355	84	33	of	of	ADP
dti-2355	84	34	clinical	clinical	ADJ
dti-2355	84	35	resolution	resolution	NOUN
dti-2355	84	36	were	be	AUX
dti-2355	84	37	observed	observe	VERB
dti-2355	84	38	during	during	ADP
dti-2355	84	39	the	the	DET
dti-2355	84	40	induction	induction	NOUN
dti-2355	84	41	phase	phase	NOUN
dti-2355	84	42	,	,	PUNCT
dti-2355	84	43	for	for	ADP
dti-2355	84	44	both	both	CCONJ
dti-2355	84	45	erythrodermic	erythrodermic	ADJ
dti-2355	84	46	psoriasis	psoriasis	NOUN
dti-2355	84	47	and	and	CCONJ
dti-2355	84	48	palmoplantar	palmoplantar	NOUN
dti-2355	84	49	fig	fig	PROPN
dti-2355	84	50	.	.	PUNCT
dti-2355	85	1	1	1	NUM
dti-2355	85	2	widespread	widespread	ADJ
dti-2355	85	3	erythrodermic	erythrodermic	ADJ
dti-2355	85	4	psoriasis	psoriasis	NOUN
dti-2355	85	5	(	(	PUNCT
dti-2355	85	6	a	a	NOUN
dti-2355	85	7	)	)	PUNCT
dti-2355	85	8	and	and	CCONJ
dti-2355	85	9	palmoplantar	palmoplantar	PROPN
dti-2355	85	10	hyperkeratosis	hyperkeratosis	PROPN
dti-2355	85	11	(	(	PUNCT
dti-2355	85	12	b	b	NOUN
dti-2355	85	13	,	,	PUNCT
dti-2355	85	14	c	c	NOUN
dti-2355	85	15	)	)	PUNCT
dti-2355	85	16	at	at	ADP
dti-2355	85	17	initial	initial	ADJ
dti-2355	85	18	presentation	presentation	NOUN
dti-2355	85	19	before	before	ADP
dti-2355	85	20	secukinumab	secukinumab	NOUN
dti-2355	85	21	treatment	treatment	NOUN
dti-2355	85	22	.	.	PUNCT
dti-2355	86	1	(	(	PUNCT
dti-2355	86	2	a	a	X
dti-2355	86	3	)	)	PUNCT
dti-2355	86	4	(	(	PUNCT
dti-2355	86	5	b	b	X
dti-2355	86	6	)	)	PUNCT
dti-2355	86	7	(	(	PUNCT
dti-2355	86	8	c	c	NOUN
dti-2355	86	9	)	)	PUNCT
dti-2355	86	10	novel	novel	ADJ
dti-2355	86	11	biologic	biologic	NOUN
dti-2355	86	12	therapy	therapy	NOUN
dti-2355	86	13	for	for	ADP
dti-2355	86	14	psoriasis	psoriasis	NOUN
dti-2355	86	15	management4	management4	NOUN
dti-2355	87	1	©	©	ADP
dti-2355	87	2	2022	2022	NUM
dti-2355	88	1	the	the	DET
dti-2355	88	2	authors	author	NOUN
dti-2355	88	3	.	.	PUNCT
dti-2355	89	1	drug	drug	NOUN
dti-2355	89	2	target	target	NOUN
dti-2355	89	3	insights	insight	NOUN
dti-2355	89	4	issn	issn	VERB
dti-2355	89	5	1177	1177	NUM
dti-2355	89	6	-	-	SYM
dti-2355	89	7	3928	3928	NUM
dti-2355	89	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2355	89	9	hyperkeratosis	hyperkeratosis	NOUN
dti-2355	89	10	.	.	PUNCT
dti-2355	90	1	the	the	DET
dti-2355	90	2	patient	patient	NOUN
dti-2355	90	3	is	be	AUX
dti-2355	90	4	currently	currently	ADV
dti-2355	90	5	under	under	ADP
dti-2355	90	6	maintenance	maintenance	NOUN
dti-2355	90	7	treatment	treatment	NOUN
dti-2355	90	8	with	with	ADP
dti-2355	90	9	secukinumab	secukinumab	NOUN
dti-2355	90	10	and	and	CCONJ
dti-2355	90	11	his	his	PRON
dti-2355	90	12	general	general	ADJ
dti-2355	90	13	condition	condition	NOUN
dti-2355	90	14	is	be	AUX
dti-2355	90	15	good	good	ADJ
dti-2355	90	16	.	.	PUNCT
dti-2355	91	1	the	the	DET
dti-2355	91	2	pasi	pasi	PROPN
dti-2355	91	3	score	score	NOUN
dti-2355	91	4	at	at	ADP
dti-2355	91	5	the	the	DET
dti-2355	91	6	first	first	ADJ
dti-2355	91	7	visit	visit	NOUN
dti-2355	91	8	was	be	AUX
dti-2355	91	9	60	60	NUM
dti-2355	91	10	,	,	PUNCT
dti-2355	91	11	and	and	CCONJ
dti-2355	91	12	decreased	decrease	VERB
dti-2355	91	13	to	to	ADP
dti-2355	91	14	20	20	NUM
dti-2355	91	15	after	after	ADP
dti-2355	91	16	induction	induction	NOUN
dti-2355	91	17	(	(	PUNCT
dti-2355	91	18	shown	show	VERB
dti-2355	91	19	in	in	ADP
dti-2355	91	20	fig	fig	NOUN
dti-2355	91	21	.	.	PUNCT
dti-2355	92	1	2a	2a	NUM
dti-2355	92	2	-	-	PUNCT
dti-2355	92	3	c	c	NOUN
dti-2355	92	4	)	)	PUNCT
dti-2355	92	5	.	.	PUNCT
dti-2355	93	1	at	at	ADP
dti-2355	93	2	a	a	DET
dti-2355	93	3	follow	follow	VERB
dti-2355	93	4	-	-	PUNCT
dti-2355	93	5	up	up	ADP
dti-2355	93	6	visit	visit	NOUN
dti-2355	93	7	,	,	PUNCT
dti-2355	93	8	conducted	conduct	VERB
dti-2355	93	9	at	at	ADP
dti-2355	93	10	the	the	DET
dti-2355	93	11	end	end	NOUN
dti-2355	93	12	of	of	ADP
dti-2355	93	13	february	february	PROPN
dti-2355	93	14	2021	2021	NUM
dti-2355	93	15	,	,	PUNCT
dti-2355	93	16	the	the	DET
dti-2355	93	17	patient	patient	NOUN
dti-2355	93	18	showed	show	VERB
dti-2355	93	19	an	an	DET
dti-2355	93	20	almost	almost	ADV
dti-2355	93	21	complete	complete	ADJ
dti-2355	93	22	remission	remission	NOUN
dti-2355	93	23	,	,	PUNCT
dti-2355	93	24	with	with	ADP
dti-2355	93	25	a	a	DET
dti-2355	93	26	pasi	pasi	NOUN
dti-2355	93	27	score	score	NOUN
dti-2355	93	28	of	of	ADP
dti-2355	93	29	10	10	NUM
dti-2355	93	30	.	.	PUNCT
dti-2355	94	1	as	as	ADP
dti-2355	94	2	of	of	ADP
dti-2355	94	3	january	january	PROPN
dti-2355	94	4	2022	2022	NUM
dti-2355	94	5	the	the	DET
dti-2355	94	6	patient	patient	NOUN
dti-2355	94	7	,	,	PUNCT
dti-2355	94	8	in	in	ADP
dti-2355	94	9	perfect	perfect	ADJ
dti-2355	94	10	health	health	NOUN
dti-2355	94	11	conditions	condition	NOUN
dti-2355	94	12	with	with	ADP
dti-2355	94	13	normal	normal	ADJ
dti-2355	94	14	hematochemical	hematochemical	ADJ
dti-2355	94	15	tests	test	NOUN
dti-2355	94	16	,	,	PUNCT
dti-2355	94	17	presents	present	VERB
dti-2355	94	18	a	a	DET
dti-2355	94	19	complete	complete	ADJ
dti-2355	94	20	remission	remission	NOUN
dti-2355	94	21	of	of	ADP
dti-2355	94	22	the	the	DET
dti-2355	94	23	clinical	clinical	ADJ
dti-2355	94	24	picture	picture	NOUN
dti-2355	94	25	.	.	PUNCT
dti-2355	95	1	discussion	discussion	NOUN
dti-2355	95	2	and	and	CCONJ
dti-2355	95	3	conclusions	conclusion	NOUN
dti-2355	95	4	although	although	SCONJ
dti-2355	95	5	the	the	DET
dti-2355	95	6	treatment	treatment	NOUN
dti-2355	95	7	options	option	NOUN
dti-2355	95	8	for	for	ADP
dti-2355	95	9	ep	ep	PROPN
dti-2355	95	10	have	have	AUX
dti-2355	95	11	greatly	greatly	ADV
dti-2355	95	12	expanded	expand	VERB
dti-2355	95	13	in	in	ADP
dti-2355	95	14	recent	recent	ADJ
dti-2355	95	15	years	year	NOUN
dti-2355	95	16	,	,	PUNCT
dti-2355	95	17	psoriasis	psoriasis	NOUN
dti-2355	95	18	and	and	CCONJ
dti-2355	95	19	its	its	PRON
dti-2355	95	20	severe	severe	ADJ
dti-2355	95	21	forms	form	NOUN
dti-2355	95	22	remain	remain	VERB
dti-2355	95	23	a	a	DET
dti-2355	95	24	major	major	ADJ
dti-2355	95	25	public	public	ADJ
dti-2355	95	26	health	health	NOUN
dti-2355	95	27	concern	concern	NOUN
dti-2355	95	28	.	.	PUNCT
dti-2355	96	1	treatment	treatment	NOUN
dti-2355	96	2	of	of	ADP
dti-2355	96	3	ep	ep	PROPN
dti-2355	96	4	with	with	ADP
dti-2355	96	5	secukinumab	secukinumab	NOUN
dti-2355	96	6	has	have	AUX
dti-2355	96	7	shown	show	VERB
dti-2355	96	8	promising	promise	VERB
dti-2355	96	9	and	and	CCONJ
dti-2355	96	10	encouraging	encourage	VERB
dti-2355	96	11	clinical	clinical	ADJ
dti-2355	96	12	outcomes	outcome	NOUN
dti-2355	96	13	,	,	PUNCT
dti-2355	96	14	and	and	CCONJ
dti-2355	96	15	the	the	DET
dti-2355	96	16	present	present	ADJ
dti-2355	96	17	case	case	NOUN
dti-2355	96	18	report	report	NOUN
dti-2355	96	19	showed	show	VERB
dti-2355	96	20	data	datum	NOUN
dti-2355	96	21	consistent	consistent	ADJ
dti-2355	96	22	with	with	ADP
dti-2355	96	23	other	other	ADJ
dti-2355	96	24	case	case	NOUN
dti-2355	96	25	reports	report	VERB
dti-2355	96	26	from	from	ADP
dti-2355	96	27	the	the	DET
dti-2355	96	28	literature	literature	NOUN
dti-2355	96	29	.	.	PUNCT
dti-2355	97	1	weng	weng	PROPN
dti-2355	97	2	et	et	PROPN
dti-2355	97	3	al	al	PROPN
dti-2355	97	4	(	(	PUNCT
dti-2355	97	5	19	19	NUM
dti-2355	97	6	)	)	PUNCT
dti-2355	97	7	reported	report	VERB
dti-2355	97	8	a	a	DET
dti-2355	97	9	series	series	NOUN
dti-2355	97	10	of	of	ADP
dti-2355	97	11	10	10	NUM
dti-2355	97	12	cases	case	NOUN
dti-2355	97	13	in	in	ADP
dti-2355	97	14	which	which	DET
dti-2355	97	15	secukinumab	secukinumab	NOUN
dti-2355	97	16	was	be	AUX
dti-2355	97	17	prescribed	prescribe	VERB
dti-2355	97	18	for	for	ADP
dti-2355	97	19	ep	ep	PROPN
dti-2355	97	20	.	.	PUNCT
dti-2355	98	1	data	datum	NOUN
dti-2355	98	2	from	from	ADP
dti-2355	98	3	those	those	DET
dti-2355	98	4	case	case	NOUN
dti-2355	98	5	reports	report	NOUN
dti-2355	98	6	showed	show	VERB
dti-2355	98	7	that	that	SCONJ
dti-2355	98	8	at	at	ADP
dti-2355	98	9	week	week	NOUN
dti-2355	98	10	16	16	NUM
dti-2355	98	11	,	,	PUNCT
dti-2355	98	12	4/10	4/10	NUM
dti-2355	98	13	patients	patient	NOUN
dti-2355	98	14	and	and	CCONJ
dti-2355	98	15	7/10	7/10	NUM
dti-2355	98	16	patients	patient	NOUN
dti-2355	98	17	,	,	PUNCT
dti-2355	98	18	respectively	respectively	ADV
dti-2355	98	19	,	,	PUNCT
dti-2355	98	20	were	be	AUX
dti-2355	98	21	able	able	ADJ
dti-2355	98	22	to	to	PART
dti-2355	98	23	achieve	achieve	VERB
dti-2355	98	24	pasi	pasi	NOUN
dti-2355	98	25	90	90	NUM
dti-2355	98	26	and	and	CCONJ
dti-2355	98	27	pasi	pasi	VERB
dti-2355	98	28	75	75	NUM
dti-2355	98	29	scores	score	NOUN
dti-2355	98	30	(	(	PUNCT
dti-2355	98	31	19	19	NUM
dti-2355	98	32	)	)	PUNCT
dti-2355	98	33	.	.	PUNCT
dti-2355	99	1	in	in	ADP
dti-2355	99	2	this	this	DET
dti-2355	99	3	very	very	ADV
dti-2355	99	4	first	first	ADJ
dti-2355	99	5	and	and	CCONJ
dti-2355	99	6	unique	unique	ADJ
dti-2355	99	7	case	case	NOUN
dti-2355	99	8	for	for	ADP
dti-2355	99	9	our	our	PRON
dti-2355	99	10	clinical	clinical	ADJ
dti-2355	99	11	practice	practice	NOUN
dti-2355	99	12	,	,	PUNCT
dti-2355	99	13	the	the	DET
dti-2355	99	14	patient	patient	NOUN
dti-2355	99	15	,	,	PUNCT
dti-2355	99	16	affected	affect	VERB
dti-2355	99	17	by	by	ADP
dti-2355	99	18	palmoplantar	palmoplantar	NOUN
dti-2355	99	19	psoriasis	psoriasis	NOUN
dti-2355	99	20	,	,	PUNCT
dti-2355	99	21	but	but	CCONJ
dti-2355	99	22	who	who	PRON
dti-2355	99	23	also	also	ADV
dti-2355	99	24	presented	present	VERB
dti-2355	99	25	a	a	DET
dti-2355	99	26	very	very	ADV
dti-2355	99	27	severe	severe	ADJ
dti-2355	99	28	form	form	NOUN
dti-2355	99	29	of	of	ADP
dti-2355	99	30	ep	ep	PROPN
dti-2355	99	31	,	,	PUNCT
dti-2355	99	32	showed	show	VERB
dti-2355	99	33	significant	significant	ADJ
dti-2355	99	34	signs	sign	NOUN
dti-2355	99	35	of	of	ADP
dti-2355	99	36	clinical	clinical	ADJ
dti-2355	99	37	resolution	resolution	NOUN
dti-2355	99	38	during	during	ADP
dti-2355	99	39	the	the	DET
dti-2355	99	40	induction	induction	NOUN
dti-2355	99	41	phase	phase	NOUN
dti-2355	99	42	,	,	PUNCT
dti-2355	99	43	with	with	ADP
dti-2355	99	44	few	few	ADJ
dti-2355	99	45	side	side	NOUN
dti-2355	99	46	effects	effect	NOUN
dti-2355	99	47	.	.	PUNCT
dti-2355	100	1	the	the	DET
dti-2355	100	2	initial	initial	ADJ
dti-2355	100	3	pasi	pasi	NOUN
dti-2355	100	4	score	score	NOUN
dti-2355	100	5	of	of	ADP
dti-2355	100	6	the	the	DET
dti-2355	100	7	patient	patient	NOUN
dti-2355	100	8	was	be	AUX
dti-2355	100	9	60	60	NUM
dti-2355	100	10	,	,	PUNCT
dti-2355	100	11	which	which	PRON
dti-2355	100	12	significantly	significantly	ADV
dti-2355	100	13	decreased	decrease	VERB
dti-2355	100	14	to	to	ADP
dti-2355	100	15	20	20	NUM
dti-2355	100	16	after	after	ADP
dti-2355	100	17	the	the	DET
dti-2355	100	18	induction	induction	NOUN
dti-2355	100	19	and	and	CCONJ
dti-2355	100	20	to	to	ADP
dti-2355	100	21	10	10	NUM
dti-2355	100	22	after	after	ADP
dti-2355	100	23	the	the	DET
dti-2355	100	24	follow	follow	VERB
dti-2355	100	25	-	-	PUNCT
dti-2355	100	26	up	up	ADP
dti-2355	100	27	visit	visit	NOUN
dti-2355	100	28	at	at	ADP
dti-2355	100	29	6	6	NUM
dti-2355	100	30	months	month	NOUN
dti-2355	100	31	,	,	PUNCT
dti-2355	100	32	suggesting	suggest	VERB
dti-2355	100	33	complete	complete	ADJ
dti-2355	100	34	remission	remission	NOUN
dti-2355	100	35	of	of	ADP
dti-2355	100	36	ep	ep	PROPN
dti-2355	100	37	.	.	PUNCT
dti-2355	101	1	however	however	ADV
dti-2355	101	2	,	,	PUNCT
dti-2355	101	3	although	although	SCONJ
dti-2355	101	4	treatment	treatment	NOUN
dti-2355	101	5	outcomes	outcome	NOUN
dti-2355	101	6	with	with	ADP
dti-2355	101	7	secukinumab	secukinumab	NOUN
dti-2355	101	8	are	be	AUX
dti-2355	101	9	promising	promise	VERB
dti-2355	101	10	,	,	PUNCT
dti-2355	101	11	additional	additional	ADJ
dti-2355	101	12	controlled	control	VERB
dti-2355	101	13	trials	trial	NOUN
dti-2355	101	14	with	with	ADP
dti-2355	101	15	extended	extended	ADJ
dti-2355	101	16	follow	follow	NOUN
dti-2355	101	17	-	-	PUNCT
dti-2355	101	18	up	up	NOUN
dti-2355	101	19	are	be	AUX
dti-2355	101	20	needed	need	VERB
dti-2355	101	21	to	to	PART
dti-2355	101	22	better	well	ADV
dti-2355	101	23	understand	understand	VERB
dti-2355	101	24	the	the	DET
dti-2355	101	25	link	link	NOUN
dti-2355	101	26	between	between	ADP
dti-2355	101	27	il-17	il-17	ADV
dti-2355	101	28	inhibition	inhibition	NOUN
dti-2355	101	29	and	and	CCONJ
dti-2355	101	30	the	the	DET
dti-2355	101	31	resolution	resolution	NOUN
dti-2355	101	32	of	of	ADP
dti-2355	101	33	ep	ep	PROPN
dti-2355	101	34	.	.	PUNCT
dti-2355	102	1	acknowledgments	acknowledgment	NOUN
dti-2355	102	2	the	the	DET
dti-2355	102	3	author	author	NOUN
dti-2355	102	4	thanks	thanks	PROPN
dti-2355	102	5	enrica	enrica	PROPN
dti-2355	102	6	piras	piras	PROPN
dti-2355	102	7	,	,	PUNCT
dti-2355	102	8	phd	phd	NOUN
dti-2355	102	9	,	,	PUNCT
dti-2355	102	10	who	who	PRON
dti-2355	102	11	provided	provide	VERB
dti-2355	102	12	editorial	editorial	ADJ
dti-2355	102	13	assistance	assistance	NOUN
dti-2355	102	14	and	and	CCONJ
dti-2355	102	15	ray	ray	PROPN
dti-2355	102	16	hill	hill	PROPN
dti-2355	102	17	,	,	PUNCT
dti-2355	102	18	an	an	DET
dti-2355	102	19	independent	independent	ADJ
dti-2355	102	20	medical	medical	ADJ
dti-2355	102	21	writer	writer	NOUN
dti-2355	102	22	,	,	PUNCT
dti-2355	102	23	who	who	PRON
dti-2355	102	24	provided	provide	VERB
dti-2355	102	25	english	english	ADJ
dti-2355	102	26	-	-	PUNCT
dti-2355	102	27	language	language	NOUN
dti-2355	102	28	editing	editing	NOUN
dti-2355	102	29	prior	prior	ADV
dti-2355	102	30	to	to	ADP
dti-2355	102	31	submission	submission	NOUN
dti-2355	102	32	on	on	ADP
dti-2355	102	33	behalf	behalf	NOUN
dti-2355	102	34	of	of	ADP
dti-2355	102	35	health	health	NOUN
dti-2355	102	36	publishing	publishing	PROPN
dti-2355	102	37	&	&	CCONJ
dti-2355	102	38	services	services	PROPN
dti-2355	102	39	srl	srl	PROPN
dti-2355	102	40	.	.	PUNCT
dti-2355	103	1	financial	financial	ADJ
dti-2355	103	2	support	support	NOUN
dti-2355	103	3	for	for	ADP
dti-2355	103	4	medical	medical	ADJ
dti-2355	103	5	editorial	editorial	ADJ
dti-2355	103	6	assistance	assistance	NOUN
dti-2355	103	7	was	be	AUX
dti-2355	103	8	provided	provide	VERB
dti-2355	103	9	by	by	ADP
dti-2355	103	10	novartis	novartis	PROPN
dti-2355	103	11	farma	farma	PROPN
dti-2355	103	12	,	,	PUNCT
dti-2355	103	13	italy	italy	PROPN
dti-2355	103	14	.	.	PUNCT
dti-2355	104	1	the	the	DET
dti-2355	104	2	funder	funder	NOUN
dti-2355	104	3	was	be	AUX
dti-2355	104	4	not	not	PART
dti-2355	104	5	involved	involve	VERB
dti-2355	104	6	in	in	ADP
dti-2355	104	7	the	the	DET
dti-2355	104	8	conception	conception	NOUN
dti-2355	104	9	,	,	PUNCT
dti-2355	104	10	drafting	drafting	NOUN
dti-2355	104	11	and	and	CCONJ
dti-2355	104	12	writing	writing	NOUN
dti-2355	104	13	of	of	ADP
dti-2355	104	14	this	this	DET
dti-2355	104	15	article	article	NOUN
dti-2355	104	16	or	or	CCONJ
dti-2355	104	17	in	in	ADP
dti-2355	104	18	the	the	DET
dti-2355	104	19	decision	decision	NOUN
dti-2355	104	20	to	to	PART
dti-2355	104	21	submit	submit	VERB
dti-2355	104	22	it	it	PRON
dti-2355	104	23	for	for	ADP
dti-2355	104	24	publication	publication	NOUN
dti-2355	104	25	.	.	PUNCT
dti-2355	105	1	author	author	NOUN
dti-2355	105	2	contributions	contributions	PROPN
dti-2355	105	3	dr	dr	PROPN
dti-2355	105	4	.	.	PROPN
dti-2355	105	5	carriero	carriero	PROPN
dti-2355	105	6	:	:	PUNCT
dti-2355	105	7	conception	conception	NOUN
dti-2355	105	8	and	and	CCONJ
dti-2355	105	9	design	design	NOUN
dti-2355	105	10	of	of	ADP
dti-2355	105	11	the	the	DET
dti-2355	105	12	work	work	NOUN
dti-2355	105	13	,	,	PUNCT
dti-2355	105	14	acquisition	acquisition	NOUN
dti-2355	105	15	and	and	CCONJ
dti-2355	105	16	analysis	analysis	NOUN
dti-2355	105	17	of	of	ADP
dti-2355	105	18	data	datum	NOUN
dti-2355	105	19	,	,	PUNCT
dti-2355	105	20	draft	draft	NOUN
dti-2355	105	21	of	of	ADP
dti-2355	105	22	the	the	DET
dti-2355	105	23	work	work	NOUN
dti-2355	105	24	;	;	PUNCT
dti-2355	105	25	agreed	agree	VERB
dti-2355	105	26	to	to	PART
dti-2355	105	27	be	be	AUX
dti-2355	105	28	accountable	accountable	ADJ
dti-2355	105	29	for	for	ADP
dti-2355	105	30	all	all	DET
dti-2355	105	31	aspects	aspect	NOUN
dti-2355	105	32	of	of	ADP
dti-2355	105	33	the	the	DET
dti-2355	105	34	work	work	NOUN
dti-2355	105	35	in	in	ADP
dti-2355	105	36	ensuring	ensure	VERB
dti-2355	105	37	that	that	SCONJ
dti-2355	105	38	questions	question	NOUN
dti-2355	105	39	related	relate	VERB
dti-2355	105	40	to	to	ADP
dti-2355	105	41	the	the	DET
dti-2355	105	42	accuracy	accuracy	NOUN
dti-2355	105	43	or	or	CCONJ
dti-2355	105	44	integrity	integrity	NOUN
dti-2355	105	45	of	of	ADP
dti-2355	105	46	any	any	DET
dti-2355	105	47	part	part	NOUN
dti-2355	105	48	of	of	ADP
dti-2355	105	49	the	the	DET
dti-2355	105	50	work	work	NOUN
dti-2355	105	51	are	be	AUX
dti-2355	105	52	appropriately	appropriately	ADV
dti-2355	105	53	investigated	investigate	VERB
dti-2355	105	54	and	and	CCONJ
dti-2355	105	55	resolved	resolve	VERB
dti-2355	105	56	.	.	PUNCT
dti-2355	106	1	statement	statement	NOUN
dti-2355	106	2	of	of	ADP
dti-2355	106	3	ethics	ethic	NOUN
dti-2355	106	4	written	write	VERB
dti-2355	106	5	informed	inform	VERB
dti-2355	106	6	consent	consent	NOUN
dti-2355	106	7	for	for	ADP
dti-2355	106	8	publication	publication	NOUN
dti-2355	106	9	(	(	PUNCT
dti-2355	106	10	including	include	VERB
dti-2355	106	11	images	image	NOUN
dti-2355	106	12	)	)	PUNCT
dti-2355	106	13	has	have	AUX
dti-2355	106	14	been	be	AUX
dti-2355	106	15	obtained	obtain	VERB
dti-2355	106	16	from	from	ADP
dti-2355	106	17	the	the	DET
dti-2355	106	18	patient	patient	NOUN
dti-2355	106	19	.	.	PUNCT
dti-2355	107	1	the	the	DET
dti-2355	107	2	research	research	NOUN
dti-2355	107	3	was	be	AUX
dti-2355	107	4	conducted	conduct	VERB
dti-2355	107	5	ethically	ethically	ADV
dti-2355	107	6	in	in	ADP
dti-2355	107	7	accordance	accordance	NOUN
dti-2355	107	8	with	with	ADP
dti-2355	107	9	the	the	DET
dti-2355	107	10	declaration	declaration	NOUN
dti-2355	107	11	of	of	ADP
dti-2355	107	12	helsinki	helsinki	PROPN
dti-2355	107	13	.	.	PUNCT
dti-2355	108	1	disclosure	disclosure	NOUN
dti-2355	108	2	conflict	conflict	NOUN
dti-2355	108	3	of	of	ADP
dti-2355	108	4	interest	interest	NOUN
dti-2355	108	5	statement	statement	NOUN
dti-2355	108	6	:	:	PUNCT
dti-2355	108	7	the	the	DET
dti-2355	108	8	author	author	NOUN
dti-2355	108	9	has	have	VERB
dti-2355	108	10	no	no	DET
dti-2355	108	11	conflicts	conflict	NOUN
dti-2355	108	12	of	of	ADP
dti-2355	108	13	interest	interest	NOUN
dti-2355	108	14	to	to	PART
dti-2355	108	15	declare	declare	VERB
dti-2355	108	16	.	.	PUNCT
dti-2355	109	1	funding	funding	NOUN
dti-2355	109	2	sources	source	NOUN
dti-2355	109	3	:	:	PUNCT
dti-2355	109	4	this	this	DET
dti-2355	109	5	research	research	NOUN
dti-2355	109	6	received	receive	VERB
dti-2355	109	7	no	no	DET
dti-2355	109	8	specific	specific	ADJ
dti-2355	109	9	grant	grant	NOUN
dti-2355	109	10	from	from	ADP
dti-2355	109	11	any	any	DET
dti-2355	109	12	funding	funding	NOUN
dti-2355	109	13	agency	agency	NOUN
dti-2355	109	14	in	in	ADP
dti-2355	109	15	the	the	DET
dti-2355	109	16	public	public	ADJ
dti-2355	109	17	,	,	PUNCT
dti-2355	109	18	commercial	commercial	ADJ
dti-2355	109	19	,	,	PUNCT
dti-2355	109	20	or	or	CCONJ
dti-2355	109	21	not	not	PART
dti-2355	109	22	-	-	PUNCT
dti-2355	109	23	for	for	ADP
dti-2355	109	24	-	-	PUNCT
dti-2355	109	25	profit	profit	NOUN
dti-2355	109	26	sectors	sector	NOUN
dti-2355	109	27	.	.	PUNCT
dti-2355	110	1	data	datum	NOUN
dti-2355	110	2	availability	availability	NOUN
dti-2355	110	3	statement	statement	NOUN
dti-2355	110	4	:	:	PUNCT
dti-2355	110	5	all	all	DET
dti-2355	110	6	data	datum	NOUN
dti-2355	110	7	generated	generate	VERB
dti-2355	110	8	or	or	CCONJ
dti-2355	110	9	analyzed	analyze	VERB
dti-2355	110	10	during	during	ADP
dti-2355	110	11	this	this	DET
dti-2355	110	12	study	study	NOUN
dti-2355	110	13	are	be	AUX
dti-2355	110	14	included	include	VERB
dti-2355	110	15	in	in	ADP
dti-2355	110	16	this	this	DET
dti-2355	110	17	article	article	NOUN
dti-2355	110	18	.	.	PUNCT
dti-2355	111	1	further	further	ADJ
dti-2355	111	2	enquiries	enquiry	NOUN
dti-2355	111	3	can	can	AUX
dti-2355	111	4	be	be	AUX
dti-2355	111	5	directed	direct	VERB
dti-2355	111	6	to	to	ADP
dti-2355	111	7	the	the	DET
dti-2355	111	8	corresponding	corresponding	ADJ
dti-2355	111	9	author	author	NOUN
dti-2355	111	10	.	.	PUNCT
dti-2355	112	1	references	reference	NOUN
dti-2355	112	2	1	1	NUM
dti-2355	112	3	.	.	PUNCT
dti-2355	112	4	rajguru	rajguru	PROPN
dti-2355	112	5	jp	jp	PROPN
dti-2355	112	6	,	,	PUNCT
dti-2355	112	7	maya	maya	PROPN
dti-2355	112	8	d	d	PROPN
dti-2355	112	9	,	,	PUNCT
dti-2355	112	10	kumar	kumar	PROPN
dti-2355	112	11	d	d	PROPN
dti-2355	112	12	,	,	PUNCT
dti-2355	112	13	suri	suri	PROPN
dti-2355	112	14	p	p	PROPN
dti-2355	112	15	,	,	PUNCT
dti-2355	112	16	bhardwaj	bhardwaj	PROPN
dti-2355	112	17	s	s	PROPN
dti-2355	112	18	,	,	PUNCT
dti-2355	112	19	patel	patel	PROPN
dti-2355	112	20	nd	nd	PROPN
dti-2355	112	21	.	.	PROPN
dti-2355	112	22	update	update	NOUN
dti-2355	112	23	on	on	ADP
dti-2355	112	24	psoriasis	psoriasis	NOUN
dti-2355	112	25	:	:	PUNCT
dti-2355	112	26	a	a	DET
dti-2355	112	27	review	review	NOUN
dti-2355	112	28	.	.	PUNCT
dti-2355	113	1	j	j	PROPN
dti-2355	113	2	family	family	PROPN
dti-2355	113	3	med	me	VERB
dti-2355	113	4	prim	prim	PROPN
dti-2355	113	5	care	care	NOUN
dti-2355	113	6	.	.	PUNCT
dti-2355	114	1	2020	2020	NUM
dti-2355	114	2	;	;	PUNCT
dti-2355	114	3	9(1):20	9(1):20	NUM
dti-2355	114	4	-	-	SYM
dti-2355	114	5	24	24	NUM
dti-2355	114	6	.	.	PUNCT
dti-2355	115	1	crossref	crossref	PROPN
dti-2355	115	2	pubmed	pubmed	PROPN
dti-2355	115	3	2	2	PROPN
dti-2355	115	4	.	.	PUNCT
dti-2355	116	1	deng	deng	PROPN
dti-2355	116	2	y	y	PROPN
dti-2355	116	3	,	,	PUNCT
dti-2355	116	4	chang	chang	PROPN
dti-2355	116	5	c	c	PROPN
dti-2355	116	6	,	,	PUNCT
dti-2355	116	7	lu	lu	PROPN
dti-2355	116	8	q.	q.	VERB
dti-2355	116	9	the	the	DET
dti-2355	116	10	inflammatory	inflammatory	ADJ
dti-2355	116	11	response	response	NOUN
dti-2355	116	12	in	in	ADP
dti-2355	116	13	psoriasis	psoriasis	NOUN
dti-2355	116	14	:	:	PUNCT
dti-2355	116	15	a	a	DET
dti-2355	116	16	comprehensive	comprehensive	ADJ
dti-2355	116	17	review	review	NOUN
dti-2355	116	18	.	.	PUNCT
dti-2355	117	1	clin	clin	PROPN
dti-2355	117	2	rev	rev	PROPN
dti-2355	117	3	allergy	allergy	PROPN
dti-2355	117	4	immunol	immunol	PROPN
dti-2355	117	5	.	.	PUNCT
dti-2355	118	1	2016	2016	NUM
dti-2355	118	2	;	;	PUNCT
dti-2355	119	1	50(3):377	50(3):377	X
dti-2355	119	2	-	-	SYM
dti-2355	119	3	389	389	NUM
dti-2355	119	4	.	.	PUNCT
dti-2355	120	1	crossref	crossref	PROPN
dti-2355	120	2	pubmed	pubmed	PROPN
dti-2355	120	3	fig	fig	PROPN
dti-2355	120	4	.	.	PUNCT
dti-2355	121	1	2	2	NUM
dti-2355	121	2	improved	improve	VERB
dti-2355	121	3	erythrodermic	erythrodermic	NOUN
dti-2355	121	4	(	(	PUNCT
dti-2355	121	5	a	a	NOUN
dti-2355	121	6	)	)	PUNCT
dti-2355	121	7	and	and	CCONJ
dti-2355	121	8	palmoplantar	palmoplantar	PROPN
dti-2355	121	9	hyperkeratosis	hyperkeratosis	PROPN
dti-2355	121	10	(	(	PUNCT
dti-2355	121	11	b	b	NOUN
dti-2355	121	12	,	,	PUNCT
dti-2355	121	13	c	c	NOUN
dti-2355	121	14	)	)	PUNCT
dti-2355	121	15	after	after	ADP
dti-2355	121	16	secukinumab	secukinumab	NOUN
dti-2355	121	17	treatment	treatment	PROPN
dti-2355	121	18	.	.	PUNCT
dti-2355	122	1	(	(	PUNCT
dti-2355	122	2	a	a	X
dti-2355	122	3	)	)	PUNCT
dti-2355	122	4	(	(	PUNCT
dti-2355	122	5	b	b	X
dti-2355	122	6	)	)	PUNCT
dti-2355	122	7	(	(	PUNCT
dti-2355	122	8	c	c	X
dti-2355	122	9	)	)	PUNCT
dti-2355	122	10	https://doi.org/10.4103/jfmpc.jfmpc_689_19	https://doi.org/10.4103/jfmpc.jfmpc_689_19	ADV
dti-2355	122	11	https://www.ncbi.nlm.nih.gov/pubmed/32110559	https://www.ncbi.nlm.nih.gov/pubmed/32110559	X
dti-2355	122	12	https://doi.org/10.1007/s12016-016-8535-x	https://doi.org/10.1007/s12016-016-8535-x	PROPN
dti-2355	122	13	https://www.ncbi.nlm.nih.gov/pubmed/27025861	https://www.ncbi.nlm.nih.gov/pubmed/27025861	PROPN
dti-2355	122	14	carriero	carriero	PROPN
dti-2355	122	15	drug	drug	NOUN
dti-2355	122	16	target	target	NOUN
dti-2355	122	17	insights	insight	NOUN
dti-2355	122	18	2022	2022	NUM
dti-2355	122	19	;	;	PUNCT
dti-2355	122	20	16	16	NUM
dti-2355	122	21	:	:	SYM
dti-2355	122	22	5	5	NUM
dti-2355	122	23	©	©	PROPN
dti-2355	122	24	2022	2022	NUM
dti-2355	122	25	the	the	DET
dti-2355	122	26	authors	author	NOUN
dti-2355	122	27	.	.	PUNCT
dti-2355	123	1	published	publish	VERB
dti-2355	123	2	by	by	ADP
dti-2355	123	3	aboutscience	aboutscience	NOUN
dti-2355	123	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2355	123	5	3	3	NUM
dti-2355	123	6	.	.	PUNCT
dti-2355	124	1	armstrong	armstrong	PROPN
dti-2355	124	2	aw	aw	PROPN
dti-2355	124	3	,	,	PUNCT
dti-2355	124	4	read	read	VERB
dti-2355	124	5	c.	c.	PROPN
dti-2355	124	6	pathophysiology	pathophysiology	NOUN
dti-2355	124	7	,	,	PUNCT
dti-2355	124	8	clinical	clinical	ADJ
dti-2355	124	9	presentation	presentation	NOUN
dti-2355	124	10	,	,	PUNCT
dti-2355	124	11	and	and	CCONJ
dti-2355	124	12	treatment	treatment	NOUN
dti-2355	124	13	of	of	ADP
dti-2355	124	14	psoriasis	psoriasis	NOUN
dti-2355	124	15	:	:	PUNCT
dti-2355	124	16	a	a	DET
dti-2355	124	17	review	review	NOUN
dti-2355	124	18	.	.	PUNCT
dti-2355	125	1	jama	jama	PROPN
dti-2355	125	2	.	.	PUNCT
dti-2355	126	1	2020;323(19):19451960	2020;323(19):19451960	X
dti-2355	126	2	.	.	PUNCT
dti-2355	127	1	crossref	crossref	PROPN
dti-2355	127	2	pubmed	pubmed	PROPN
dti-2355	127	3	4	4	PROPN
dti-2355	127	4	.	.	PUNCT
dti-2355	128	1	reynolds	reynolds	PROPN
dti-2355	128	2	ka	ka	PROPN
dti-2355	128	3	,	,	PUNCT
dti-2355	128	4	pithadia	pithadia	PROPN
dti-2355	128	5	dj	dj	PROPN
dti-2355	128	6	,	,	PUNCT
dti-2355	128	7	lee	lee	PROPN
dti-2355	128	8	eb	eb	PROPN
dti-2355	128	9	,	,	PUNCT
dti-2355	128	10	liao	liao	PROPN
dti-2355	128	11	w	w	PROPN
dti-2355	128	12	,	,	PUNCT
dti-2355	128	13	wu	wu	PROPN
dti-2355	128	14	jj	jj	PROPN
dti-2355	128	15	.	.	PROPN
dti-2355	129	1	a	a	DET
dti-2355	129	2	systematic	systematic	ADJ
dti-2355	129	3	review	review	NOUN
dti-2355	129	4	of	of	ADP
dti-2355	129	5	treatment	treatment	NOUN
dti-2355	129	6	strategies	strategy	NOUN
dti-2355	129	7	for	for	ADP
dti-2355	129	8	erythrodermic	erythrodermic	ADJ
dti-2355	129	9	psoriasis	psoriasis	NOUN
dti-2355	129	10	.	.	PUNCT
dti-2355	130	1	j	j	PROPN
dti-2355	130	2	dermatolog	dermatolog	PROPN
dti-2355	130	3	treat	treat	NOUN
dti-2355	130	4	.	.	PUNCT
dti-2355	131	1	2021;32(1):49	2021;32(1):49	NUM
dti-2355	131	2	-	-	SYM
dti-2355	131	3	55	55	NUM
dti-2355	131	4	.	.	PUNCT
dti-2355	132	1	crossref	crossref	PROPN
dti-2355	132	2	pubmed	pubmed	PROPN
dti-2355	132	3	5	5	PROPN
dti-2355	132	4	.	.	PUNCT
dti-2355	133	1	carrasquillo	carrasquillo	PROPN
dti-2355	133	2	oy	oy	PROPN
dti-2355	133	3	,	,	PUNCT
dti-2355	133	4	pabón	pabón	NOUN
dti-2355	133	5	-	-	PUNCT
dti-2355	133	6	cartagena	cartagena	NOUN
dti-2355	133	7	g	g	PROPN
dti-2355	133	8	,	,	PUNCT
dti-2355	133	9	falto	falto	NOUN
dti-2355	133	10	-	-	PUNCT
dti-2355	133	11	aizpurua	aizpurua	PROPN
dti-2355	133	12	la	la	PROPN
dti-2355	133	13	,	,	PUNCT
dti-2355	133	14	et	et	PROPN
dti-2355	133	15	al	al	PROPN
dti-2355	133	16	.	.	PUNCT
dti-2355	133	17	treatment	treatment	NOUN
dti-2355	133	18	of	of	ADP
dti-2355	133	19	erythrodermic	erythrodermic	ADJ
dti-2355	133	20	psoriasis	psoriasis	NOUN
dti-2355	133	21	with	with	ADP
dti-2355	133	22	biologics	biologic	NOUN
dti-2355	133	23	:	:	PUNCT
dti-2355	133	24	a	a	DET
dti-2355	133	25	systematic	systematic	ADJ
dti-2355	133	26	review	review	NOUN
dti-2355	133	27	.	.	PUNCT
dti-2355	134	1	j	j	PROPN
dti-2355	134	2	am	be	AUX
dti-2355	134	3	acad	acad	ADJ
dti-2355	134	4	dermatol	dermatol	NOUN
dti-2355	134	5	.	.	PUNCT
dti-2355	135	1	2020;83(1):151	2020;83(1):151	NUM
dti-2355	135	2	-	-	SYM
dti-2355	135	3	158	158	NUM
dti-2355	135	4	.	.	PUNCT
dti-2355	136	1	crossref	crossref	PROPN
dti-2355	136	2	pubmed	pubmed	PROPN
dti-2355	136	3	6	6	NUM
dti-2355	136	4	.	.	PUNCT
dti-2355	137	1	singh	singh	PROPN
dti-2355	137	2	rk	rk	PROPN
dti-2355	137	3	,	,	PUNCT
dti-2355	137	4	lee	lee	PROPN
dti-2355	137	5	km	km	PROPN
dti-2355	137	6	,	,	PUNCT
dti-2355	137	7	ucmak	ucmak	PROPN
dti-2355	137	8	d	d	NOUN
dti-2355	137	9	,	,	PUNCT
dti-2355	137	10	et	et	PROPN
dti-2355	137	11	al	al	PROPN
dti-2355	137	12	.	.	PROPN
dti-2355	137	13	erythrodermic	erythrodermic	ADJ
dti-2355	137	14	psoriasis	psoriasis	NOUN
dti-2355	137	15	:	:	PUNCT
dti-2355	137	16	pathophysiology	pathophysiology	NOUN
dti-2355	137	17	and	and	CCONJ
dti-2355	137	18	current	current	ADJ
dti-2355	137	19	treatment	treatment	NOUN
dti-2355	137	20	perspectives	perspective	NOUN
dti-2355	137	21	.	.	PUNCT
dti-2355	138	1	psoriasis	psoriasis	NOUN
dti-2355	138	2	(	(	PUNCT
dti-2355	138	3	auckl	auckl	NOUN
dti-2355	138	4	)	)	PUNCT
dti-2355	138	5	.	.	PUNCT
dti-2355	139	1	2016;6:93	2016;6:93	NOUN
dti-2355	139	2	-	-	PUNCT
dti-2355	139	3	104	104	NUM
dti-2355	139	4	.	.	PUNCT
dti-2355	140	1	crossref	crossref	PROPN
dti-2355	140	2	pubmed	pubmed	PROPN
dti-2355	140	3	7	7	PROPN
dti-2355	140	4	.	.	PUNCT
dti-2355	141	1	fitch	fitch	PROPN
dti-2355	141	2	e	e	PROPN
dti-2355	141	3	,	,	PUNCT
dti-2355	141	4	harper	harper	NOUN
dti-2355	141	5	e	e	PROPN
dti-2355	141	6	,	,	PUNCT
dti-2355	141	7	skorcheva	skorcheva	PROPN
dti-2355	141	8	i	i	PROPN
dti-2355	141	9	,	,	PUNCT
dti-2355	141	10	kurtz	kurtz	PROPN
dti-2355	141	11	se	se	PROPN
dti-2355	141	12	,	,	PUNCT
dti-2355	141	13	blauvelt	blauvelt	PROPN
dti-2355	141	14	a.	a.	NOUN
dti-2355	141	15	pathophysiology	pathophysiology	NOUN
dti-2355	141	16	of	of	ADP
dti-2355	141	17	psoriasis	psoriasis	NOUN
dti-2355	141	18	:	:	PUNCT
dti-2355	141	19	recent	recent	ADJ
dti-2355	141	20	advances	advance	NOUN
dti-2355	141	21	on	on	ADP
dti-2355	141	22	il-23	il-23	NOUN
dti-2355	141	23	and	and	CCONJ
dti-2355	141	24	th17	th17	PROPN
dti-2355	141	25	cytokines	cytokine	NOUN
dti-2355	141	26	.	.	PUNCT
dti-2355	142	1	curr	curr	PROPN
dti-2355	142	2	rheumatol	rheumatol	PROPN
dti-2355	142	3	rep	rep	PROPN
dti-2355	142	4	.	.	PROPN
dti-2355	142	5	2007;9(6):461	2007;9(6):461	NUM
dti-2355	142	6	-	-	SYM
dti-2355	142	7	467	467	NUM
dti-2355	142	8	.	.	PUNCT
dti-2355	143	1	crossref	crossref	PROPN
dti-2355	143	2	pubmed	pubmed	PROPN
dti-2355	143	3	8	8	PROPN
dti-2355	143	4	.	.	PUNCT
dti-2355	144	1	berg	berg	PROPN
dti-2355	144	2	sh	sh	PROPN
dti-2355	144	3	,	,	PUNCT
dti-2355	144	4	balogh	balogh	PROPN
dti-2355	144	5	ea	ea	PROPN
dti-2355	144	6	,	,	PUNCT
dti-2355	144	7	ghamrawi	ghamrawi	PROPN
dti-2355	144	8	ri	ri	PROPN
dti-2355	144	9	,	,	PUNCT
dti-2355	144	10	feldman	feldman	PROPN
dti-2355	144	11	sr	sr	PROPN
dti-2355	144	12	.	.	PUNCT
dti-2355	145	1	a	a	DET
dti-2355	145	2	review	review	NOUN
dti-2355	145	3	of	of	ADP
dti-2355	145	4	secukinumab	secukinumab	NOUN
dti-2355	145	5	in	in	ADP
dti-2355	145	6	psoriasis	psoriasis	NOUN
dti-2355	145	7	treatment	treatment	NOUN
dti-2355	145	8	.	.	PUNCT
dti-2355	146	1	immunotherapy	immunotherapy	NOUN
dti-2355	146	2	.	.	PUNCT
dti-2355	147	1	2021	2021	NUM
dti-2355	147	2	;	;	PUNCT
dti-2355	147	3	13(3):201	13(3):201	NUM
dti-2355	147	4	-	-	SYM
dti-2355	147	5	216	216	NUM
dti-2355	147	6	.	.	PUNCT
dti-2355	148	1	crossref	crossref	PROPN
dti-2355	148	2	pubmed	pubmed	PROPN
dti-2355	148	3	9	9	PROPN
dti-2355	148	4	.	.	PUNCT
dti-2355	148	5	chiricozzi	chiricozzi	PROPN
dti-2355	148	6	a	a	PROPN
dti-2355	148	7	,	,	PUNCT
dti-2355	148	8	krueger	krueger	PROPN
dti-2355	148	9	jg	jg	PROPN
dti-2355	148	10	.	.	PROPN
dti-2355	148	11	il-17	il-17	PROPN
dti-2355	148	12	targeted	target	VERB
dti-2355	148	13	therapies	therapy	NOUN
dti-2355	148	14	for	for	ADP
dti-2355	148	15	psoriasis	psoriasis	NOUN
dti-2355	148	16	.	.	PUNCT
dti-2355	149	1	expert	expert	NOUN
dti-2355	149	2	opin	opin	NOUN
dti-2355	149	3	investig	investig	NOUN
dti-2355	149	4	drugs	drug	NOUN
dti-2355	149	5	.	.	PUNCT
dti-2355	150	1	2013;22(8):993	2013;22(8):993	PROPN
dti-2355	150	2	-	-	PUNCT
dti-2355	150	3	1005	1005	NUM
dti-2355	150	4	.	.	PUNCT
dti-2355	151	1	crossref	crossref	PROPN
dti-2355	151	2	pubmed	pubmed	PROPN
dti-2355	151	3	10	10	PROPN
dti-2355	151	4	.	.	PUNCT
dti-2355	152	1	wasilewska	wasilewska	PROPN
dti-2355	152	2	a	a	DET
dti-2355	152	3	,	,	PUNCT
dti-2355	152	4	winiarska	winiarska	NOUN
dti-2355	152	5	m	m	PROPN
dti-2355	152	6	,	,	PUNCT
dti-2355	152	7	olszewska	olszewska	PROPN
dti-2355	152	8	m	m	PROPN
dti-2355	152	9	,	,	PUNCT
dti-2355	152	10	rudnicka	rudnicka	NOUN
dti-2355	152	11	l.	l.	PROPN
dti-2355	152	12	interleukin-17	interleukin-17	PROPN
dti-2355	152	13	inhibitors	inhibitor	NOUN
dti-2355	152	14	.	.	PUNCT
dti-2355	153	1	a	a	DET
dti-2355	153	2	new	new	ADJ
dti-2355	153	3	era	era	NOUN
dti-2355	153	4	in	in	ADP
dti-2355	153	5	treatment	treatment	NOUN
dti-2355	153	6	of	of	ADP
dti-2355	153	7	psoriasis	psoriasis	NOUN
dti-2355	153	8	and	and	CCONJ
dti-2355	153	9	other	other	ADJ
dti-2355	153	10	skin	skin	NOUN
dti-2355	153	11	diseases	disease	NOUN
dti-2355	153	12	.	.	PUNCT
dti-2355	154	1	postepy	postepy	ADJ
dti-2355	154	2	dermatol	dermatol	NOUN
dti-2355	154	3	alergol	alergol	NOUN
dti-2355	154	4	.	.	PUNCT
dti-2355	155	1	2016;33(4):247	2016;33(4):247	PROPN
dti-2355	155	2	-	-	SYM
dti-2355	155	3	252	252	NUM
dti-2355	155	4	.	.	PUNCT
dti-2355	156	1	crossref	crossref	PROPN
dti-2355	156	2	pubmed	pubmed	PROPN
dti-2355	156	3	11	11	NUM
dti-2355	156	4	.	.	PUNCT
dti-2355	157	1	reich	reich	PROPN
dti-2355	157	2	k	k	PROPN
dti-2355	157	3	,	,	PUNCT
dti-2355	157	4	warren	warren	PROPN
dti-2355	157	5	rb	rb	PROPN
dti-2355	157	6	,	,	PUNCT
dti-2355	157	7	coates	coates	PROPN
dti-2355	157	8	lc	lc	PROPN
dti-2355	157	9	,	,	PUNCT
dti-2355	157	10	di	di	X
dti-2355	157	11	comite	comite	PROPN
dti-2355	157	12	g.	g.	PROPN
dti-2355	157	13	long	long	ADJ
dti-2355	157	14	-	-	PUNCT
dti-2355	157	15	term	term	NOUN
dti-2355	157	16	efficacy	efficacy	NOUN
dti-2355	157	17	and	and	CCONJ
dti-2355	157	18	safety	safety	NOUN
dti-2355	157	19	of	of	ADP
dti-2355	157	20	secukinumab	secukinumab	NOUN
dti-2355	157	21	in	in	ADP
dti-2355	157	22	the	the	DET
dti-2355	157	23	treatment	treatment	NOUN
dti-2355	157	24	of	of	ADP
dti-2355	157	25	the	the	DET
dti-2355	157	26	multiple	multiple	ADJ
dti-2355	157	27	manifestations	manifestation	NOUN
dti-2355	157	28	of	of	ADP
dti-2355	157	29	psoriatic	psoriatic	ADJ
dti-2355	157	30	disease	disease	NOUN
dti-2355	157	31	.	.	PUNCT
dti-2355	158	1	j	j	PROPN
dti-2355	158	2	eur	eur	PROPN
dti-2355	158	3	acad	acad	PROPN
dti-2355	158	4	dermatol	dermatol	NOUN
dti-2355	158	5	venereol	venereol	NOUN
dti-2355	158	6	.	.	PUNCT
dti-2355	159	1	2020;34(6):1161	2020;34(6):1161	NUM
dti-2355	159	2	-	-	SYM
dti-2355	159	3	1173	1173	NUM
dti-2355	159	4	.	.	PUNCT
dti-2355	160	1	crossref	crossref	PROPN
dti-2355	160	2	pubmed	pubmed	PROPN
dti-2355	160	3	12	12	NUM
dti-2355	160	4	.	.	PUNCT
dti-2355	161	1	deodhar	deodhar	PROPN
dti-2355	161	2	a	a	DET
dti-2355	161	3	,	,	PUNCT
dti-2355	161	4	mease	mease	PROPN
dti-2355	161	5	pj	pj	PROPN
dti-2355	161	6	,	,	PUNCT
dti-2355	161	7	mcinnes	mcinnes	PROPN
dti-2355	161	8	ib	ib	PROPN
dti-2355	161	9	,	,	PUNCT
dti-2355	161	10	et	et	PROPN
dti-2355	161	11	al	al	PROPN
dti-2355	161	12	.	.	PUNCT
dti-2355	162	1	long	long	ADJ
dti-2355	162	2	-	-	PUNCT
dti-2355	162	3	term	term	NOUN
dti-2355	162	4	safety	safety	NOUN
dti-2355	162	5	of	of	ADP
dti-2355	162	6	secukinumab	secukinumab	NOUN
dti-2355	162	7	in	in	ADP
dti-2355	162	8	patients	patient	NOUN
dti-2355	162	9	with	with	ADP
dti-2355	162	10	moderate	moderate	ADJ
dti-2355	162	11	-	-	PUNCT
dti-2355	162	12	to	to	ADP
dti-2355	162	13	-	-	PUNCT
dti-2355	162	14	severe	severe	ADJ
dti-2355	162	15	plaque	plaque	NOUN
dti-2355	162	16	psoriasis	psoriasis	NOUN
dti-2355	162	17	,	,	PUNCT
dti-2355	162	18	psoriatic	psoriatic	ADJ
dti-2355	162	19	arthritis	arthritis	NOUN
dti-2355	162	20	,	,	PUNCT
dti-2355	162	21	and	and	CCONJ
dti-2355	162	22	ankylosing	ankylose	VERB
dti-2355	162	23	spondylitis	spondylitis	NOUN
dti-2355	162	24	:	:	PUNCT
dti-2355	162	25	integrated	integrate	VERB
dti-2355	162	26	pooled	pool	VERB
dti-2355	162	27	clinical	clinical	ADJ
dti-2355	162	28	trial	trial	NOUN
dti-2355	162	29	and	and	CCONJ
dti-2355	162	30	post	post	ADJ
dti-2355	162	31	-	-	ADJ
dti-2355	162	32	marketing	marketing	ADJ
dti-2355	162	33	surveillance	surveillance	NOUN
dti-2355	162	34	data	datum	NOUN
dti-2355	162	35	.	.	PUNCT
dti-2355	163	1	arthritis	arthritis	NOUN
dti-2355	163	2	res	re	NOUN
dti-2355	163	3	ther	ther	ADV
dti-2355	163	4	.	.	PUNCT
dti-2355	164	1	2019;21(1):111	2019;21(1):111	NUM
dti-2355	164	2	.	.	PUNCT
dti-2355	165	1	crossref	crossref	PROPN
dti-2355	165	2	13	13	NUM
dti-2355	165	3	.	.	PUNCT
dti-2355	166	1	baraliakos	baraliakos	PROPN
dti-2355	166	2	x	x	PROPN
dti-2355	166	3	,	,	PUNCT
dti-2355	166	4	gossec	gossec	PROPN
dti-2355	166	5	l	l	NOUN
dti-2355	166	6	,	,	PUNCT
dti-2355	166	7	pournara	pournara	NOUN
dti-2355	166	8	e	e	NOUN
dti-2355	166	9	,	,	PUNCT
dti-2355	166	10	et	et	PROPN
dti-2355	166	11	al	al	PROPN
dti-2355	166	12	.	.	PROPN
dti-2355	166	13	secukinumab	secukinumab	PROPN
dti-2355	166	14	in	in	ADP
dti-2355	166	15	patients	patient	NOUN
dti-2355	166	16	with	with	ADP
dti-2355	166	17	psoriatic	psoriatic	ADJ
dti-2355	166	18	arthritis	arthritis	NOUN
dti-2355	166	19	and	and	CCONJ
dti-2355	166	20	axial	axial	ADJ
dti-2355	166	21	manifestations	manifestation	NOUN
dti-2355	166	22	:	:	PUNCT
dti-2355	166	23	results	result	NOUN
dti-2355	166	24	from	from	ADP
dti-2355	166	25	the	the	DET
dti-2355	166	26	double	double	ADJ
dti-2355	166	27	-	-	PUNCT
dti-2355	166	28	blind	blind	ADJ
dti-2355	166	29	,	,	PUNCT
dti-2355	166	30	randomised	randomise	VERB
dti-2355	166	31	,	,	PUNCT
dti-2355	166	32	phase	phase	NOUN
dti-2355	166	33	3	3	NUM
dti-2355	166	34	maximise	maximise	NOUN
dti-2355	166	35	trial	trial	NOUN
dti-2355	166	36	.	.	PUNCT
dti-2355	167	1	ann	ann	PROPN
dti-2355	167	2	rheum	rheum	PROPN
dti-2355	167	3	dis	dis	PROPN
dti-2355	167	4	.	.	PUNCT
dti-2355	168	1	2021;80(5):582	2021;80(5):582	NUM
dti-2355	168	2	-	-	PUNCT
dti-2355	168	3	590	590	NUM
dti-2355	168	4	.	.	PUNCT
dti-2355	169	1	crossref	crossref	PROPN
dti-2355	169	2	pubmed	pubmed	PROPN
dti-2355	169	3	14	14	NUM
dti-2355	169	4	.	.	PUNCT
dti-2355	170	1	kiltz	kiltz	PROPN
dti-2355	170	2	u	u	PROPN
dti-2355	170	3	,	,	PUNCT
dti-2355	170	4	sfikakis	sfikakis	PROPN
dti-2355	170	5	pp	pp	PROPN
dti-2355	170	6	,	,	PUNCT
dti-2355	170	7	gaffney	gaffney	PROPN
dti-2355	170	8	k	k	PROPN
dti-2355	170	9	,	,	PUNCT
dti-2355	170	10	et	et	PROPN
dti-2355	170	11	al	al	PROPN
dti-2355	170	12	.	.	PROPN
dti-2355	170	13	secukinumab	secukinumab	PROPN
dti-2355	170	14	use	use	NOUN
dti-2355	170	15	in	in	ADP
dti-2355	170	16	patients	patient	NOUN
dti-2355	170	17	with	with	ADP
dti-2355	170	18	moderate	moderate	ADJ
dti-2355	170	19	to	to	ADP
dti-2355	170	20	severe	severe	ADJ
dti-2355	170	21	psoriasis	psoriasis	NOUN
dti-2355	170	22	,	,	PUNCT
dti-2355	170	23	psoriatic	psoriatic	ADJ
dti-2355	170	24	arthritis	arthritis	NOUN
dti-2355	170	25	and	and	CCONJ
dti-2355	170	26	ankylosing	ankylose	VERB
dti-2355	170	27	spondylitis	spondylitis	NOUN
dti-2355	170	28	in	in	ADP
dti-2355	170	29	real	real	ADJ
dti-2355	170	30	-	-	PUNCT
dti-2355	170	31	world	world	NOUN
dti-2355	170	32	setting	setting	NOUN
dti-2355	170	33	in	in	ADP
dti-2355	170	34	europe	europe	PROPN
dti-2355	170	35	:	:	PUNCT
dti-2355	170	36	baseline	baseline	PROPN
dti-2355	170	37	data	datum	NOUN
dti-2355	170	38	from	from	ADP
dti-2355	170	39	serena	serena	PROPN
dti-2355	170	40	study	study	PROPN
dti-2355	170	41	.	.	PUNCT
dti-2355	171	1	adv	adv	INTJ
dti-2355	171	2	ther	ther	ADV
dti-2355	171	3	.	.	PUNCT
dti-2355	172	1	2020;37(6):2865	2020;37(6):2865	NUM
dti-2355	172	2	-	-	SYM
dti-2355	172	3	2883	2883	NUM
dti-2355	172	4	.	.	PUNCT
dti-2355	173	1	crossref	crossref	PROPN
dti-2355	173	2	pubmed	pubmed	PROPN
dti-2355	173	3	15	15	PROPN
dti-2355	173	4	.	.	PUNCT
dti-2355	174	1	cosentx	cosentx	VERB
dti-2355	174	2	-	-	PUNCT
dti-2355	174	3	summary	summary	NOUN
dti-2355	174	4	of	of	ADP
dti-2355	174	5	product	product	NOUN
dti-2355	174	6	characteristics	characteristic	NOUN
dti-2355	174	7	.	.	PUNCT
dti-2355	175	1	available	available	ADJ
dti-2355	175	2	at	at	ADP
dti-2355	175	3	:	:	PUNCT
dti-2355	175	4	online	online	INTJ
dti-2355	175	5	(	(	PUNCT
dti-2355	175	6	accessed	access	VERB
dti-2355	175	7	october	october	PROPN
dti-2355	175	8	2021	2021	NUM
dti-2355	175	9	)	)	PUNCT
dti-2355	175	10	.	.	PUNCT
dti-2355	176	1	16	16	NUM
dti-2355	176	2	.	.	PUNCT
dti-2355	177	1	frieder	frieder	PROPN
dti-2355	177	2	j	j	PROPN
dti-2355	177	3	,	,	PUNCT
dti-2355	177	4	kivelevitch	kivelevitch	PROPN
dti-2355	177	5	d	d	PROPN
dti-2355	177	6	,	,	PUNCT
dti-2355	177	7	menter	menter	PROPN
dti-2355	177	8	a.	a.	NOUN
dti-2355	177	9	secukinumab	secukinumab	PROPN
dti-2355	177	10	:	:	PUNCT
dti-2355	177	11	a	a	DET
dti-2355	177	12	review	review	NOUN
dti-2355	177	13	of	of	ADP
dti-2355	177	14	the	the	DET
dti-2355	177	15	anti	anti	ADJ
dti-2355	177	16	-	-	ADJ
dti-2355	177	17	il-17a	il-17a	ADJ
dti-2355	177	18	biologic	biologic	NOUN
dti-2355	177	19	for	for	ADP
dti-2355	177	20	the	the	DET
dti-2355	177	21	treatment	treatment	NOUN
dti-2355	177	22	of	of	ADP
dti-2355	177	23	psoriasis	psoriasis	NOUN
dti-2355	177	24	.	.	PUNCT
dti-2355	178	1	ther	ther	VERB
dti-2355	178	2	adv	adv	PROPN
dti-2355	178	3	chronic	chronic	ADJ
dti-2355	178	4	dis	dis	PROPN
dti-2355	178	5	.	.	PUNCT
dti-2355	179	1	2018;9(1):5	2018;9(1):5	PROPN
dti-2355	179	2	-	-	PUNCT
dti-2355	179	3	21	21	NUM
dti-2355	179	4	.	.	PUNCT
dti-2355	180	1	crossref	crossref	PROPN
dti-2355	180	2	pubmed	pubmed	PROPN
dti-2355	180	3	17	17	NUM
dti-2355	180	4	.	.	PUNCT
dti-2355	181	1	langley	langley	PROPN
dti-2355	181	2	rg	rg	PROPN
dti-2355	181	3	,	,	PUNCT
dti-2355	181	4	elewski	elewski	PROPN
dti-2355	181	5	be	be	AUX
dti-2355	181	6	,	,	PUNCT
dti-2355	181	7	lebwohl	lebwohl	PROPN
dti-2355	181	8	m	m	PROPN
dti-2355	181	9	,	,	PUNCT
dti-2355	181	10	et	et	PROPN
dti-2355	181	11	al	al	PROPN
dti-2355	181	12	;	;	PUNCT
dti-2355	181	13	erasure	erasure	VERB
dti-2355	181	14	study	study	NOUN
dti-2355	181	15	group	group	NOUN
dti-2355	181	16	;	;	PUNCT
dti-2355	181	17	fixture	fixture	ADJ
dti-2355	181	18	study	study	NOUN
dti-2355	181	19	group	group	NOUN
dti-2355	181	20	.	.	PUNCT
dti-2355	182	1	secukinumab	secukinumab	NOUN
dti-2355	182	2	in	in	ADP
dti-2355	182	3	plaque	plaque	NOUN
dti-2355	182	4	psoriasis	psoriasis	NOUN
dti-2355	182	5	—	—	PUNCT
dti-2355	182	6	results	result	NOUN
dti-2355	182	7	of	of	ADP
dti-2355	182	8	two	two	NUM
dti-2355	182	9	phase	phase	NOUN
dti-2355	182	10	3	3	NUM
dti-2355	182	11	trials	trial	NOUN
dti-2355	182	12	.	.	PUNCT
dti-2355	183	1	n	n	PROPN
dti-2355	183	2	engl	engl	PROPN
dti-2355	183	3	j	j	PROPN
dti-2355	183	4	med	med	PROPN
dti-2355	183	5	.	.	PUNCT
dti-2355	184	1	2014;371(4):326338	2014;371(4):326338	NUM
dti-2355	184	2	.	.	PUNCT
dti-2355	185	1	crossref	crossref	PROPN
dti-2355	185	2	pubmed	pubmed	PROPN
dti-2355	185	3	18	18	NUM
dti-2355	185	4	.	.	PUNCT
dti-2355	186	1	damiani	damiani	PROPN
dti-2355	186	2	g	g	PROPN
dti-2355	186	3	,	,	PUNCT
dti-2355	186	4	pacifico	pacifico	NOUN
dti-2355	186	5	a	a	PRON
dti-2355	186	6	,	,	PUNCT
dti-2355	186	7	russo	russo	PROPN
dti-2355	186	8	f	f	PROPN
dti-2355	186	9	,	,	PUNCT
dti-2355	186	10	et	et	PROPN
dti-2355	186	11	al	al	PROPN
dti-2355	186	12	.	.	PUNCT
dti-2355	186	13	use	use	NOUN
dti-2355	186	14	of	of	ADP
dti-2355	186	15	secukinumab	secukinumab	NOUN
dti-2355	186	16	in	in	ADP
dti-2355	186	17	a	a	DET
dti-2355	186	18	cohort	cohort	NOUN
dti-2355	186	19	of	of	ADP
dti-2355	186	20	erythrodermic	erythrodermic	ADJ
dti-2355	186	21	psoriatic	psoriatic	ADJ
dti-2355	186	22	patients	patient	NOUN
dti-2355	186	23	:	:	PUNCT
dti-2355	186	24	a	a	DET
dti-2355	186	25	pilot	pilot	NOUN
dti-2355	186	26	study	study	NOUN
dti-2355	186	27	.	.	PUNCT
dti-2355	187	1	j	j	PROPN
dti-2355	187	2	clin	clin	PROPN
dti-2355	187	3	med	med	PROPN
dti-2355	187	4	.	.	PUNCT
dti-2355	188	1	2019;8(6):770	2019;8(6):770	X
dti-2355	188	2	.	.	PUNCT
dti-2355	189	1	crossref	crossref	PROPN
dti-2355	189	2	pubmed	pubmed	PROPN
dti-2355	189	3	19	19	NUM
dti-2355	189	4	.	.	PUNCT
dti-2355	190	1	weng	weng	PROPN
dti-2355	190	2	hj	hj	PROPN
dti-2355	190	3	,	,	PUNCT
dti-2355	190	4	wang	wang	PROPN
dti-2355	190	5	ts	ts	PROPN
dti-2355	190	6	,	,	PUNCT
dti-2355	190	7	tsai	tsai	PROPN
dti-2355	190	8	tf	tf	INTJ
dti-2355	190	9	.	.	PUNCT
dti-2355	191	1	clinical	clinical	ADJ
dti-2355	191	2	experience	experience	NOUN
dti-2355	191	3	of	of	ADP
dti-2355	191	4	secukinumab	secukinumab	NOUN
dti-2355	191	5	in	in	ADP
dti-2355	191	6	the	the	DET
dti-2355	191	7	treatment	treatment	NOUN
dti-2355	191	8	of	of	ADP
dti-2355	191	9	erythrodermic	erythrodermic	ADJ
dti-2355	191	10	psoriasis	psoriasis	NOUN
dti-2355	191	11	:	:	PUNCT
dti-2355	191	12	a	a	DET
dti-2355	191	13	case	case	NOUN
dti-2355	191	14	series	series	NOUN
dti-2355	191	15	.	.	PUNCT
dti-2355	192	1	br	br	PROPN
dti-2355	192	2	j	j	PROPN
dti-2355	192	3	dermatol	dermatol	NOUN
dti-2355	192	4	.	.	PUNCT
dti-2355	193	1	2018;178(6):1439	2018;178(6):1439	NUM
dti-2355	193	2	-	-	SYM
dti-2355	193	3	1440	1440	NUM
dti-2355	193	4	.	.	PUNCT
dti-2355	194	1	crossref	crossref	PROPN
dti-2355	194	2	pubmed	pubmed	PROPN
dti-2355	194	3	https://doi.org/10.1001/jama.2020.4006	https://doi.org/10.1001/jama.2020.4006	PROPN
dti-2355	194	4	https://www.ncbi.nlm.nih.gov/pubmed/32427307	https://www.ncbi.nlm.nih.gov/pubmed/32427307	NUM
dti-2355	194	5	https://doi.org/10.1080/09546634.2019.1689228	https://doi.org/10.1080/09546634.2019.1689228	PROPN
dti-2355	194	6	https://www.ncbi.nlm.nih.gov/pubmed/31682547	https://www.ncbi.nlm.nih.gov/pubmed/31682547	X
dti-2355	194	7	https://doi.org/10.1016/j.jaad.2020.03.073	https://doi.org/10.1016/j.jaad.2020.03.073	PROPN
dti-2355	194	8	https://www.ncbi.nlm.nih.gov/pubmed/32247872	https://www.ncbi.nlm.nih.gov/pubmed/32247872	NUM
dti-2355	194	9	https://doi.org/10.2147/ptt.s101232	https://doi.org/10.2147/ptt.s101232	PROPN
dti-2355	194	10	https://www.ncbi.nlm.nih.gov/pubmed/28856115	https://www.ncbi.nlm.nih.gov/pubmed/28856115	X
dti-2355	194	11	https://doi.org/10.1007/s11926-007-0075-1	https://doi.org/10.1007/s11926-007-0075-1	PROPN
dti-2355	194	12	https://www.ncbi.nlm.nih.gov/pubmed/18177599	https://www.ncbi.nlm.nih.gov/pubmed/18177599	DET
dti-2355	194	13	https://doi.org/10.2217/imt-2020-0195	https://doi.org/10.2217/imt-2020-0195	NOUN
dti-2355	194	14	https://www.ncbi.nlm.nih.gov/pubmed/33203276	https://www.ncbi.nlm.nih.gov/pubmed/33203276	INTJ
dti-2355	194	15	https://doi.org/10.1517/13543784.2013.806483	https://doi.org/10.1517/13543784.2013.806483	PROPN
dti-2355	194	16	https://www.ncbi.nlm.nih.gov/pubmed/23731078	https://www.ncbi.nlm.nih.gov/pubmed/23731078	PROPN
dti-2355	194	17	https://doi.org/10.5114/ada.2016.61599	https://doi.org/10.5114/ada.2016.61599	VERB
dti-2355	194	18	https://www.ncbi.nlm.nih.gov/pubmed/27605893	https://www.ncbi.nlm.nih.gov/pubmed/27605893	NUM
dti-2355	194	19	https://doi.org/10.1111/jdv.16124	https://doi.org/10.1111/jdv.16124	PROPN
dti-2355	194	20	https://www.ncbi.nlm.nih.gov/pubmed/31785165	https://www.ncbi.nlm.nih.gov/pubmed/31785165	NUM
dti-2355	194	21	https://doi.org/10.1186/s13075-019-1882-2	https://doi.org/10.1186/s13075-019-1882-2	NUM
dti-2355	194	22	https://doi.org/10.1136/annrheumdis-2020-218808	https://doi.org/10.1136/annrheumdis-2020-218808	NOUN
dti-2355	194	23	https://www.ncbi.nlm.nih.gov/pubmed/33334727	https://www.ncbi.nlm.nih.gov/pubmed/33334727	X
dti-2355	194	24	https://doi.org/10.1007/s12325-020-01352-8	https://doi.org/10.1007/s12325-020-01352-8	NUM
dti-2355	194	25	https://www.ncbi.nlm.nih.gov/pubmed/32378070	https://www.ncbi.nlm.nih.gov/pubmed/32378070	NUM
dti-2355	194	26	https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf	https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf	PROPN
dti-2355	194	27	https://doi.org/10.1177/2040622317738910	https://doi.org/10.1177/2040622317738910	NOUN
dti-2355	194	28	https://www.ncbi.nlm.nih.gov/pubmed/29344327	https://www.ncbi.nlm.nih.gov/pubmed/29344327	NOUN
dti-2355	194	29	https://doi.org/10.1056/nejmoa1314258	https://doi.org/10.1056/nejmoa1314258	NOUN
dti-2355	194	30	https://www.ncbi.nlm.nih.gov/pubmed/25007392	https://www.ncbi.nlm.nih.gov/pubmed/25007392	ADP
dti-2355	194	31	https://doi.org/10.3390/jcm8060770	https://doi.org/10.3390/jcm8060770	NOUN
dti-2355	194	32	https://www.ncbi.nlm.nih.gov/pubmed/31159169	https://www.ncbi.nlm.nih.gov/pubmed/31159169	X
dti-2355	194	33	https://doi.org/10.1111/bjd.16252	https://doi.org/10.1111/bjd.16252	PROPN
dti-2355	194	34	https://www.ncbi.nlm.nih.gov/pubmed/29265175	https://www.ncbi.nlm.nih.gov/pubmed/29265175	X